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INVITED LECTURES
DEVELOPMENT OF MOLECULAR IMAGING BIOMARKERS
B. Gulyás
Psychiatry Section, Department of Clinical Neuroscience, Karolinska Institute,
Stockholm, Sweden
Biomarkers are anatomical, physiological, biochemical or molecular parameters
associated with the presence and severity of specific pathophysiological and/or
disease states. With various methodologies they can be objectively measured, para-
metrically quantified and evaluated as indicators of normal biological processes,
pathological processes or pharmacological responses to a therapeutic interven-
tion.
Molecular imaging biomarkers are means that can visualize disease biomarkers
with the help of molecular imaging techniques, including PET. They have a tremen-
dous potential for (i) the early diagnosis of diseases, (ii) accelerating the develop-
ment of pharmaceuticals, (iii) following up therapies and (iv) designing individual
medications ("personalized medicine").
The search for molecular imaging biomarkers has in recent years become one of
the primary objectives of PET research world-wide, as PET imaging biomarkers
may have multiple benefits: (i) They can be important imaging tools in drug devel-
opment studies by the visualization of drug effects on molecular target systems; (ii)
they can help researchers to identify surrogate endpoints of normal and patholog-
ical biochemical and physiological processes in the living organisms; (iii) they can
be used as diagnostic agents for the early diagnosis of various diseases, and (iv)
they can be important progression indicators during the follow-up of medical treat-
ments.
The presentation will survey the principles of imaging biomarker developments for
PET studies and give particular examples, based upon the Karolinska PET center's
research and development activities, regarding imaging biomarkers for neuropsy-
chiatric drug development, neuroinflammation and neurodegeneration.
NUCLEAR DIAGNOSTICS OF BRAIN DISEASES
Zs. Szabó
Johns Hopkins University School of Medicine, Baltimore, MD, United States
Both single photon emission tomography (SPECT) and positron emission tomog-
raphy (PET) can be used for molecular imaging of brain diseases. Hybrid PET/CT
and SPECT/CT scanners improve anatomical localization of lesions, and localiza-
tion is further enhanced with PET/MRI registration or direct PET/MRI hybrid imag-
ing. Most notable clinical applications are brain tumors, epilepsy and dementia.
Less frequent utilizations include motor disorders, inflammation, trauma and cere-
brovascular diseases.
In dementia, PET can provide characteristic patterns for Alzheimer's disease and
frontotemporal degeneration, and has been used for assessment of disease sever-
ity and prediction of long term outcome. Characteristic changes have also been
described for Lewy body dementia and posterior cortical atrophy.
Primary brain tumors can accurately be diagnosed with contrast MRI while PET can
be implemented for differentiation of post-radiation inflammatory changes from re-
current glioma. Radiolabeled amino acids will delineate low grade astrocytomas. In
patients with HIV infection, both FDG PET and thallium SPECT have been used for
differentiation of CNS lymphoma from toxoplasmosis. In children with medulloblas-
toma, whole body PET/CT has been used for detection of recurrent local, and dis-
tant metastatic disease.
When scalp EEG and MRI are inconclusive, both SPECT and PET can provide lo-
calization and surgery guidance in mesial temporal lobe seizures, which repre-
sents the most frequent form of lesional partial epilepsy. Ictal SPECT and interictal
PET are less reliable for localization of extratemporal forms of epilepsy.
LABELLING OF BIO-MACROMOLECULES: CHALLENGE
IN RADIOLABELLING FOR RADIOPHARMACY
J. Steinbach
Institute of Radiopharmacy, Forschungszentrum Dresden-Rossendorf, Dresden,
Germany
Over the last two decades, radiolabeled antibodies and peptides have been intro-
duced in research and in clinical application of nuclear medicine. Such substances
are utilized for tumor targeting as radiotracers and for therapeutic purposes as well.
Labelling of such substances with PET radionuclides such as F-18 offers the chance
of introduction the label without drastic changes of the molecular properties in con-
junction with highest image quality, i.e. high diagnostic value. Radiometal-labeled
bioactive substances offer both: The possibility of diagnostics and therapeutic in-
tervention as well. However, the labelling procedure is a considerable alteration of
the molecules radiopharmacological properties. This is due to the need of intro-
ducing a chelating moiety to bind the radiometals kinetically and thermodynami-
cally inert. Beside this geometric impact, the labelling conditions are of highest
importance. Whereas peptides may withstand rather drastic conditions proteins
e.g. antibodies need ambient labelling conditions such as aqueous solution, room
temperature, near physiological pH. Furthermore, various proteins tend to coagu-
late in the presence of heavy metals as radio-copper.
The talk will present such results of scientific investigations at the Institute of Ra-
diopharmacy during the last five years. This involves the application of established
methods such as the use of [18F]SFB (N-succinimidyl-4-[18F]fluorobenzoate) for
labelling of biomolecules, the development of alternative labelling agents/prosthet-
ic groups as well as current efforts to establish methods for pre- and postlabelling
with radiometals. All these investigations are directed to corresponding applica-
tions with biomolecules and bioactive compounds, respectively.
DIAGNOSIS AND TREATMENT OF THYROID CARCINOMA
D. Piciu1, A. Irimie2, I. Duncea2, C. Lisencu1, M. Cheptea1
1Institute of Oncology ”Prof. Ion Chiricutã” Cluj-Napoca, Romania 2University
of Medicine and Pharmacy “Iuliu Hatieganu”, Cluj-Napoca, Romania
Background: The aim of the study is to review the database of thyroid carcinoma of
the Institute of Oncology “Prof. Dr. I. Chiricuþã” in Cluj-Napoca, the largest thera-
peutic centre in this field in Romania.
Material and methods: Were analyzed the latest guidelines for the diagnosis and
treatment of thyroid cancer published by the European and American Thyroid As-
sociations (ETA, ATA), and also by the British Thyroid Association, American Asso-
ciation of Clinical Endocrinologists (AACE) and Endocrine Surgeons, also by the
European Association of Nuclear Medicine (EANM), by the American and Europe-
an Societies of Clinical Oncology (ASCO and ESMO). According to these publica-
tions, the study will present the national guideline; the personal experience of the
authors will be presented in this study relying on the data more than 4000 patients,
representing more than half of all the patients with thyroid cancer registered at na-
tional level in the period from 1970 util 2008.
Results/discussion: The results present the incidence of thyroid cancer, the evolu-
tion of the frequency in the last decade after Chernobyl, the age and gender distri-
bution, the histopathology distribution and the prognosis, the evolution of the strat-
egies of treatment in this period of about 40 years, the different radioiodine doses
administered for therapeutic purposes, and their significance in the survival rate.
Conclusion: The significant increase in the incidence of thyroid cancer and the
high percentage of clinically and sonographically detected thyroid nodules in the
general population  calls for a clear and uniform strategy of diagnosis and treat-
ment of this pathology.
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ONCOLOGY — THERAPY
FDG PET-CT IN LYMPHOMA — DIFFICULTIES IN EVALUATION PROCESS
AND PITTFALLS
Garai1, A. Greenfield2, N. Fedinecz1, L. Szabados1, Á. Illés3
1PET-CT Medical Diagnostic Ltd., Debrecen, Hungary, 2University of Debrecen, Hungary,
33rd Department of Internal Medicine, Debrecen, Hungary
Nowadays the FDG PET examination has a definitive, important role in the clinical
management of patients with lymphoma. The basic condition for risk adapted treat-
ment of these patients is exact staging and early objective evaluation of the effec-
tiveness of therapy.
Based on experience obtained from lymphoma patients' routine PET-CT scan, we
analysed the difficulties of evaluation in different time frames of clinical follow up.
We studied data from 125 patients, 59 Hodgkin lymphoma (HD) and 66 non-Hodgkin
lymphoma (NHL) sufferers, according to histological type and FDG avidity, rare
types of extranodal involvement, and accompanying disease.
In accordance with the data in the literature in contrast to indolent NHL we mea-
sured higher mean FDG uptake (SUVmax) in patients with HD and aggressive type of
NHL although, in individual cases, different FDG uptake can be measured in pa-
tients with the same histology pattern. This is the reason why in the case of follow
up studies the basic examination is essential to do.
Extranodal involment has been found in 40% of the patients. In certain cases such
as liver, spleenand bone involvement the PET-CT study has higher sensitivity com-
pared to other affected organs e.g.  the bowels, brain and  bone marrow. Because
an accompanying disease may cause false results detailed anamnesis is required.
THE DIAGNOSTIC ACCURACY OF 18-FDG-PET/CT AS A RESTAGING
METHOD FOR MALIGNANT LYMPHOMAS
Zs. Molnár1, B. Deák1, Zs. Lengyel2, A. Rosta1, T. Schneider1, E. Várady1,
M. Kásler1, K. Borbély1
1National Institute of Oncology, Budapest, Hungary, 2Positron Diagnostics PET-CT Ltd.,
Budapest, Hungary
Background: Approximately two-thirds of patients suffering from Hodgkin lympho-
ma, and about half of those with aggressive diffuse large B-cell lymphoma present
residual mass after the completion of therapy. Moreover, approximately 30% of both
groups will relapse. Several studies have demonstrated the usefulness of PET/CT in
the restaging of patients with malignant lymphoma. The purpose of this study was
to test the diagnostic accuracy of PET/CT as a restaging method.
Material and methods: Between August 2005 and July 2006, PET/CT was per-
formed in 43 patients (22 with HL and 21 with NHL) after the completion of planned
treatment. PET/CT findings were analyzed retrospectively, and compared to the
clinical and/or pathological follow-up data.
Results: The sensitivity, specificity, positive predictive value and negative predic-
tive value of PET/CT were 75%, 91%, 67%, and 94%, respectively.
Conclusion: FDG-PET/CT with its high sensitivity, specificity and negative predic-
tive value proved to be a reliable restaging method. Our results confirm the recom-
mendations of the International Harmonization Project in Lymphoma (J Clin Oncol
2007; 25: 571–578) into clinical practice. Additionally, since the positive predictive
value of PET/CT is not high, the positive findings must be carefully analyzed, in-
cluding the performance of biopsy and thorough observation.
EARLY RESPONSE EVALUATION IN PATIENTS WITH HIGH GRADE
LYMPHOMA USING FDG PET/CT
Zs. Lengyel, Sz. Szakáll, K. Kajáry, P. Molnár, A. Rosta, B. Deák, T. Schneider,
E. Várady, K. Borbély, Zs. Molnár
Positron Diagnostic Ltd., Budapest, Hungary
Background: Metabolic imaging has officially been included in the response crite-
ria of lymphoma treatment since 2007 when a revised system was established un-
der the auspices of an international cooperation in the framework of the Internation-
al Harmonization Project. However, clinical trials are now aimed at the assessment
of the prognostic power of the so-called interim PET/CT scans in the early response
evaluation of lymphomas. The authors of this study present their own experiences
in this field.
Material and methods: Since January 2008, forty-five patients with high grade lym-
phoma have been investigated by interim FDG PET/CT between the second and
third chemotherapy cycles. The patients were referred from the Internal Department
“A” of National Institute of Oncology. An end-therapy scan was also performed in
nine patients. The maximal SUV of lymphoma lesions was calculated and com-
pared between different time points.
Results: In 71% of the patients (32/45) the reduction in SUVmax was more than 50%
at the interim PET compared to the baseline value. Smaller reduction in SUVmax or
progression of the disease was established in thirteen patients. In patients in whom
the reduction of SUVmax was greater than 50%, the end-therapy scan confirmed
complete metabolic remission.
Conclusions: It can be concluded in agreement with data in the literature that lym-
phomas that show a marked decrease in SUVmax at interim PET/CT are likely to
reach complete metabolic remission at the end of therapy. Further studies are needed
to elucidate the prognostic threshold of decrease in metabolic activity, the timing of
interim scan and the relation to complete pathologic remission.
18F-FDG PET/CT IN LUNG CANCER: A RETROSPECTIVE ANALYSIS
OF 415 STUDIES
M. Zsiray1, Zs. Markóczy1, M. Magyar1, Zs. Lengyel2, Sz. Szakáll2, A. Fekésházy4,
M. Kásler3, K. Borbély3
1National Korányi Institute of Pulmonology, Budapest, Hungary, 2Positron Diagnostic
Ltd., Budapest, Hungary, 3National Institute of Oncology, Budapest, Hungary, 4PET-CT
Ltd., Budapest, Hungary
Background: FDG PET is the most sensitive noninvasive imaging modality for the
evaluation of solitary pulmonary nodules (SPN). This technique is superior to CT in
terms of sensitivity and specificity for the diagnosis and staging of lung cancer.
Results of multiple studies have confirmed the benefit of FDG PET in the manage-
ment of primary lung carcinoma.  Our purpose was to evaluate the clinical impact of
PET/CT in our patients.
Material and methods: The results of PET/CT studies in 408 patients/415 studies
were analyzed, retrospectively. PET/CT studies were performed with indication of
metabolic characterization of SPN (n = 154), preoperative staging (n = 175), and
restaging (n = 86) of primary lung carcinoma.
Results: N-Staging resulted in 17 mediastinoscopies, and 54 thoracotomies.
The sensitivity, specificity, positive predictive value and negative predictive value of
18F-FDG PET/CT were 92%, 75%, 72%, and 94%, respectively.
Conclusion: The 18F-FDG PET/CT dramatically improved the sensitivity, specificity,
and diagnostic accuracy of the evaluation of our patients with lung carcinoma.
However, due to the low specificity of the method, tissue sampling of suspicious
mediastinal lymph nodes is highly recommended for the optimal selection of pa-
tients for surgery or radiotherapy.
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HOW CAN SPECT-CT HELP IN THE DIAGNOSIS OF NEUROENDOCRINE
TUMORS?
V. Tóth1, I. Balogh2, Z. Tóth1
1PET-CT Ltd., Budapest, Hungary, 2Department of Nuclear Medicine, Uzsoki Hospital,
Budapest, Hungary
Background: Neuroendocrine tumors (NET) are very rare neoplasms. Our aim was
to show the importance of combining SPECT and CT in the diagnosis of NET. Pri-
mary tumors and metastatic lesions can be detected via methods of nuclear medi-
cine. However, SPECT and CT image fusion can increase sensitivity and diagnostic
accuracy. Many times, we cannot distinguish the specific and aspecific signs (ac-
cumulation in other malignant tumors, acute and chronic inflammations) thus, in
this problem, the role of CT will be important in the future.
Material and methods: 111In-Octreoscan examinations were performed for 6 pa-
tients. We made a whole body scan and additional images, and each patient had a
SPECT examination 24, 48 and 72 hours after the iv. injection of the radiopharma-
con. In all the cases, a low-dose CT examination was also performed in an other
institute. We made fusion images using MEDISO-Interview XP Software.
Results: In every case, the accumulation of 111In-Octreoscan was detected, but in
all the patients the uptake of radioactive isotope had unusual localization and/or
uncommon extension. It was very difficult to locate many lesions without CT. Fusion
images could help to identify atypical signs.
Conclusions: The role of 111In-Octreoscan examination completed with SPECT is
very important in the diagnosis of NET. We need to detect the exact location of the
tumor and eliminate the aspecific signs. CT examination and the methods of image
fusion increased the sensitivity and accuracy of SPECT.
COMPARISON OF THE DETECTABILITY OF BONE METASTASES
BY FDG PET-CT AND BONE SCINTIGRAPHY
L. Jorgov1, A. Fekésházy5, Zs. Varga5, H. Galgóczy5, Z. Tóth5, Zs. Kopcsányi3,
Z. Galler4, T. Györke2, 5
1Faculty of Medicine, Semmelweis University, Budapest, Hungary, 2Department
of Diagnostic Radiology and Oncotherapy, Semmelweis University, Budapest, Hungary,
3Department of Nuclear Medicine, Péterfy Sándor Str. Hospital, Budapest, Hungary,
4Department of Nuclear Medicine, National Korányi Institute for TB and Pulmonology,
Budapest, Hungary, 5PET-CT Medical Diagnostics Ltd., Budapest, Hungary
Background: Both FDG PET-CT (PET) and bone scintigraphy are sensitive meth-
ods for the detection of bone metastases. We compared retrospectively the results
of these methods when both investigations were performed within one month.
Material and methods: 48 pairs of PET and bone scan investigations (96 investiga-
tions) of 46 patients (ages: 34–75 years) were compared. The primary tumors were
cancers of the breast, lung, cervix and pancreas and non-Hodgkin lymphoma. In
case all of the abnormalities could be depicted by one of the two methods we
evaluated the detectability by the other investigation. As far as bone metastases
were concerned, we determined the results on a patient by patient and a lesion by
lesion base.
Results: Patient by patient evaluation showed findings of bone metastases with
both methods in 12 cases; in 36 cases neither of the investigations raised the sus-
picion of bone metastases. PET, however, detected more single lesions in the same
patient according to the lesion by lesion analysis in 5 cases. We could not perform
lesion by lesion evaluation in 1 case because of more diffuse and conflating bone
disease.
Conclusions: For the detection of bone metastatic state bone scintigraphy and
PET provided the same effectiveness in each single patient while PET proved more
sensitive based on the lesion by lesion comparison.
FDG-PET FOR AXILLARY NODAL STAGING IN EARLY BREAST CANCER
Zs. Hascsi1, Z. Garami2, I. Garai1
1PET-CT Medical Diagnostic Ltd., Debrecen, Hungary, 2Institute of Surgery, University of
Debrecen, Medical and Health Science Center, Debrecen, Hungary
Background: Management of the axilla in operable breast cancer is of capital im-
portance, since the most powerful predictor of survival and recurrence is the status
of lymph nodes. Recently many centers introduced the less invasive axillary sam-
pling techinque of sentinel lymph node biopsy (SLNB) for axillary staging. Howev-
er, axillary lymph node dissection (ALND) is still considered as the standard exam-
ination procedure for the assessment of axillary lymph node metastases. This study
analyzed the value of [18F]-fluorodeoxyglucose positron emission tomography
(FDG-PET) in detecting axillary metastases in women with early (operable) breast
cancer.
Material and methods: Thirty-eight patients with newly diagnosed invasive breast
cancer participated in the present, prospective study. All patients had clinically
negative axilla, and underwent FDG-PET before surgery, which was complemented
with SLNB. Histopathology of ALND and SLNB were compared with the imaging
results of the axilla.
Results: The prevalence of histopathologically verified axillary metastases was 45%
(17 women). The sensitivity and specificity of FDG-PET for the detection of axillary
involvement were 82% and 95% respectively, with 1 false positive and 3 false neg-
ative cases. The semiquantitative analysis of the PET images revealed that axillary
nodal maximal standardized uptake value normalized to body weight more than 1.2
had a positive predictive value of 93%.
Conclusions: The high specificity of PET suggests that women who have focal
FDG uptake in the axilla should undergo full ALND rather than SLNB. In contrast,
there is a need for SLNB in the case of PET-negative axilla.
FDG PET/CT IN RADIOTHERAPY TREATMENT PLANNING
K. Czigner1, J. Lövey1, P. Ágoston1, J. Fodor1, Zs. Lengyel2, Cs. Polgár1,
M. Kásler1, K. Borbély1
1National Institute of Oncology, Budapest, Hungary, 2Positron Diagnostic Ltd., Budapest,
Hungary
Background: To demonstrate the importance of PET/CT in radiotherapy treatment
planning (RTP) based on our experiences.
Material and methods: PET/CT based RTP has been performed in fifty-three pa-
tients between 2006 and 2008 at our institute as follows: head and neck cancer (n
= 19), lung cancer (n = 12), lymphoma (n = 7); gynecologic (n = 3) or gastrointes-
tinal recurrence (n = 3), and sarcoma (n = 2). Pinnacle planning software was
used for fusion and planning.  The influence of PET/CT based planning on target
definition and gross tumor volume (GTV) delineation was evaluated.
Results: Radiotherapy was omitted in 3 patients (5.7%) due to distant metastases
revealed by PET/CT. In four patients (7.5%) the lesion was FDG-negative. GTV and/
or doses to different lymph node regions were changed in patients with lung can-
cer (66.7%, 8/12) and head and neck cancer (63.2%, 12/19) based on the PET/CT
data. In 2 of 7 patients (28.6%) with lymphoma residual bone involvement could be
detected and delineated only by PET/CT. CT- and PET/CT-based change in GTVs
> 20% were observed in 27/46 patients (58.69%).
Conclusion: The use of PET/CT in radiotherapy treatment planning may affect treat-
ment strategy, selection of target volumes and delineation of GTV. PET/CT based
treatment planning results in changing the target volume and/or prescribed dose in
more then 50% of the patients compared with conventional CT based planning.
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EXPERIENCE WITH SPECT/CT STUDIES IN PATIENTS
WITH DIFFERENTIATED THYROID CANCER AFTER HIGH-DOSE
RADIOTHERAPY
M. Sarkadi1, E. Mezösi2, L. Bajnok2, E. Schmidt1, Zs. Szabó1, S. Szekeres1,
K. Zámbó1
1Department of Nuclear Medicine, University of Pécs, Hungary, 21st Department of
Internal Medicine, University of Pécs, Hungary
Background: Whole body scans (WBS) completed with SPECT/CT examinations
were investigated in patients with papillary and follicular thyroid cancer after high-
dose radiotherapy. The anatomical localization and the etiology of the hot spots
were evaluated.
Material and methods: Between July 2007 and March 2009 102 examinations were
performed in 83 thyroid cancer patients. Among them 19 patients had been in-
volved in a follow-up study after the repeated therapy. Sixty four women (mean age
51 years) and 19 men (mean age 44 years) were examined on the 6th day after
radioablation. WBS, scintigraphy of the neck and completed SPECT/CT examina-
tions about the neck, the chest and the other suspect regions were evaluated.
Results: In 37 cases of the 102 studies pathological 131I cumulations were found in
the region of the head, neck, chest and/or abdomen. Among them 17 cases proved
to be metastases. The results were not obvious in 4 patients, so multislice CT and
MRI examinations were recommended. Metastasis was proved by CT without a hot
spot in 2 patients. Only remnant activity was found in 63 cases.
Conclusion: Only 46% of the hot spots on the WBS and on the completed SPECT/
/CT were verified as metastases. The completed examinations by SPECT/CT sys-
tem after WBS give more information about the etiology of the hot spots and the
staging of the disease, which has a crucial role in providing efficient therapy.
BIOLOGICAL HAZARDS OF RADIATION SYNOVECTOMY. CHROMOSOMAL
ANALYSIS OF PERIPHERAL LYMPHOCYTES OF PATIENTS BEFORE
AND AFTER RADIATION SYNOVECTOMY WITH 166-HOLMIUM-PHYTATE
M. Szentesi1, Z. Nagy2, E. Ádám3, I. Papp1, P. Géher1
1 Department of Rheumatology, Semmelweis University, Budapest, Hungary,
2Department of Nuclear Medicine, Semmelweis University, Budapest, Hungary,
3Department of Haematology, Semmelweis University, Budapest, Hungary,
Chair of Rheumatology and Physiotherapy, Polyclinic of the Hospitaller Brothers
of St. John of God, Budapest, Hungary
Background: The aim of this study was to identify any increase in specific chromo-
some-type abnormalities, using published criteria, in patients following 166-Holmi-
um-phytate (166-Ho) radiosynoviorthesis (RSO) of the knee.
Material and methods: 18 patients with rheumatoid arthritis (RA), 7 males, 11 fe-
males, mean age: 45 years (24–72) were included in the study. The cytogenetic
analysis was performed in each patient before and 4 weeks after the RSO.
Conventional cytogenetic analysis was performed on the peripheral blood sample.
Cells were incubated for 72 hours in RPMI 1640 containing 20% fetal calf serum,
antibiotics and 0.1 ml Phytohemagglutinin. Colcemid was subsequently added for
1 hour. 100 metaphases were analyzed from each sample. The following chromo-
somal aberrations were scored: ring chromosome, gap lesion, terminal and intersti-
tial deletion, translocation ring chromosome.
Results: The normal range of structural deviation is 0–4%. The pathologic rate of
chromosomal aberrations is above 5%. In our study, a ring chromosome was iden-
tified in the post-therapy sample (0.00055%) in only one case.
Conclusion: There was no increase in the scored chromosome-type abnormalities
after 166-Ho RSO. This study further supports the relative safety of 166-Holmium-
phytate compared to other radiopharmaceuticals.
EFFECTIVENESS OF REPEATED YTTRIUM-90 MULTIBONE THERAPY
ON PAINFUL BONE METASTASIS
I. Balogh, Gy. Kovács, A. Medveczki
Uzsoki Teaching Hospital, Budapest, Hungary
Backround: As we have presented earlier, the Yttrium-90 Multibone therapy is an
efficient method for relieving pain in patients suffering from metastatic bone pain.
What is the effect of repeated therapy?
Material and methods: Over the past 10 years, we have retreated 24 out of 215
patients. The total number of pretreatments was 68, in which the number of patients/
/number of therapies was as follows: 12/2, 7/3, 3/4, 1/5, and 1/6. Nineteen out of the
24 patients complained of painful breathing, and 5 of them suffered from painful
prostate cancer. We analyzed the degree and duration of the pain-killing/analgesic
effect, and the changes of lesions by repeated bone scan (on 0–3 scale system).
Result: The number of patients/duration of the pain-killing/analgesic effect, (in
months) was as follows: 3/3, 15/4–12, 3/12–24, and 3/ > 24. No irreversible side
effect was detected — the blood count changes were the same as in the case of
single therapy. So there was not any cumulative side effect. No correlation was
found between the positivity of bone scintigraphy (the number and/or intensity of
the lesions) and the effectiveness of the therapy either.
Conclusion: We can conclude that the mean duration of the pain-killing effect was
longer in the case of repeated therapy. There was not any correlation between the
severity of the illness and the effectiveness; even in serious cases, long pain-free
periods were experienced without any irreversible side effect.
EFFICACY OF REPEATED USE OF SM-153-EDTMP FOR PAIN PALLIATION
IN PATIENTS WITH BONE METASTASIS OF BREAST CANCER
A. Radácsi2, E. Takács2, J. Kocsis3, , K. Tóth3, I. Szilvási1
1State Health Centre, Department of Nuclear Medicine, Budapest, Hungary, 2Department
of Nuclear Medicine, Semmelweis University, Budapest, Hungary, 33rd Department
of Internal Medicine, Semmelweis University, Budapest, Hungary
Backround: The objective of this study was to evaluate therapeutic efficacy and
bone marrow toxicity of repeated application of Samarium-153-ethylene-diamine-
tetramethylene phosphonate (Sm-153-EDTMP) for bone pain palliation in patients
with multiple bone metastases from breast cancer.
Material and methods: 22 consecutive patients with painful multiple bone me-
tastases and significant (mild: n = 7, good: n = 11 or excellent: n = 4) pain relief
without severe hematological side effects after a standard therapeutic dose of
Sm-153-EDTMP were enrolled in a prospective study. All patients had repeated
injection of Sm-153-EDTMP. The second activity was the same as the first one.
Between the two applications of Sm-153-EDTMP chemotherapeutic protocols were
continued. The therapeutic effect and hematological toxicity (using NCI toxicity in-
dex) of the first and the second injection of Sm-153-EDTMP were compared. The
therapeutic effect was evaluated by using Karnofsky performance score and dura-
tion of pain palliation, using interviews before and after 18 weeks of the treatment.
Results: The second treatment was effective in all patients. No differences of im-
provements on Karnofsky scale were found. The numbers of patients with mild,
good or excellent pain relief were 9, 9 and 4 respectively. The mean duration of pain
reduction after the first and the second therapeutic dose was 14.2 and 13.4 weeks
(p > 0.05). There were no statistically significant differences in the decrease of
granulocytes and platelets, but red blood corpuscles were moderately fewer after
the second injection.
Conclusions: The second application of Sm-153-EDTMP is of the same therapeu-
tic efficacy (in terms of pain palliation and duration of effect) and is characterized
by similar bone marrow toxicity.
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SPECT CT EXAMINATION OF ASPECIFIC MDP CUMULATIONS
S. Szekeres, E. Schmidt, Zs. Szabó, K. Zámbó
Deparment of Nuclear Medicine, University of Pécs, Hungary
Background: We aimed to evaluate the etiology of aspecific cumulations detected
on bone scintigraphy by the SPECT-CT imaging system.
Material and methods: We used the data of 17 patients obtained by 99mTc-MDP
bone scintigraphy, in the period between September 2007 and March 2009. The
selected patients were detected with aspecific cumulation not related to bone tis-
sue. In order to define the exact anatomical position and etiology of the cumulation,
a SPECT-CT examination was performed. Most of the bone scintigraphy examina-
tions of these 17 patients were carried out for control purposes or staging known
malignancies. The remaining group was examined for bone pain of unknown ori-
gin.
Results: In 7 cases the increase of radiopharmaceuticals was due to/because of
malignancy. In 6 patients aspecific enrichment was proven to be of benign origin.
In 4 patients isotope accumulation was due to urine flow obstruction in the upper
urinary tract.
Conclusion: SPECT-CT imaging is an effective examination to diagnose cumula-
tion detected using bone scintigraphy unrelated to bone structure. In most of the
cases it revealed the benign or malignant origin of the lesion and could be utilized
to recommend further adequate diagnostic procedures.
WHOLE BODY BONE SCINTIGRAPHY IN ASSESSING THE THERAPEUTIC
EFFECT OF BIPHOSPHONATES IN PATIENTS WITH BONE METASTASES
E. Takács1, A. Radácsi1, É.K. Tóth2, J. Kocsis2, M. Szucs3, G. Bánfi3, I. Szilvási1
1Deptartment of Nuclear Medicine, Semmelweis University, Budapest, Hungary,
23rd Deptartment of Internal Medicine, Semmelweis University, Budapest, Hungary,
3Department of Urology Semmelweis University, Budapest, Hungary
Background: The aim of this retrospective study was to evaluate the role of whole
body bone scintigraphy (WBS) in monitoring the therapeutic effect of biphospho-
nates in patients with documented multiple bone metastases.
Material and methods: 24 patients (7 males and 17 females, aged 51 to 83 years)
were studied. Thirteen of them had breast cancer, 5 had lung cancer and 6 had
prostate cancer. Two WBSs (after i.v. injection of 740 MBq Tc-99m-MDP) were per-
formed in each patients: the first one before the start of the treatment with new-
generation biphosphonates (ibandronic acid, zolendronate or pamidronate) and
the second one 6 months thereafter. The number and intensity of scintigraphic
lesions were compared in all patients.
Results: After biphosphonate treatment no bone lesions were visualized in 3 (12.5%)
patients; the number and/or the intensity of the lesions were decreased in 9 (37.5%)
patients; no change was seen in 5 patients (21%). Seven patients (29%) showed
progression on bone scintigraphy.
Conclusions: A total of 50% of patients had a complete or partial scintigraphic
improvement after biphosphonate treatment. The whole body bone scintigraphy is
a useful imaging modality for assessing the effect of the biphosphonate therapy in
patients with bone metastases. The clinical significance of "bone scintigraphic re-
mission" needs further investigation.
THE ROLE OF BONE SCINTIGRAPHY IN THE DIAGNOSIS OF SAPHO
SYNDROME
E. Schmidt1, B. Keszthelyi2, K. Dérczy3, K. Zámbó1
1Department of Nuclear Medicine, University of Pécs, Hungary, 2Hospital Zsigmondy
Vilmos, Harkány, Hungary, 3Department of Radiology, University of Pécs, Hungary
Background: SAPHO syndrome includes a variety of inflammatory bone disorders
that may be associated with skin changes, such as Synovitis, Acne, Pustulosis,
Hyperostosis and Osteitis. Bone scintigraphy can play a significant role in the diag-
nosis beside other imaging methods. The aim of our work is to draw attention of
SAPHO syndrome through the introduction of two cases, since the complex and
varied symptoms can be confusing.
Material and methods:
1st patient: 51-year-old male, who had signs of local inflammation on the left and
right shins at the age of 20for the first time and at the age of 21 for the second time,
respectively. These symptoms recurred several times a year. Later, symptoms char-
acteristic of acne and pustular changes appeared on the skin. Occasional non-
steroid therapy had a positive effect on the clinical symptoms, however antibiotics
were ineffective.
The 3-phase bone scintigraphy shows a 10–12 cm long increased activity in the
blood-pool and bone phase in the middle part of the diaphysis of the left tiba,
proving the irritation.
2nd patient: 38-year-old female. A year ago, the medial end of her right clavicle
became swollen and, in addition, acne and pustulosis appeared in the gluteal re-
gion. The laboratory examinations did not yield pathological results. The bone scan
showed increased isotope accumulation in the right sternoclavicular joint.
Results/Conclusions: Although SAPHO syndrome has no specific therapy, recently
several publications have reported positive effects of biphosphates. The precondi-
tion of using the appropriate therapy is a correct diagnosis, bone scintigraphy play-
ing an important role in making it.
IMAGING
THE MINIPET PROJECT IN DEBRECEN
L. Trón1, M. Emri1, G. Opposits1, S.A. Kis1, L. Ács1, L. Balkay1, J. Imrek3,
D. Novák2, Gy. Hegyesi2, I. Valastyán2, I. Bagaméry3, J. Molnár2
1Institute of Nuclear Medicine, University of Debrecen, Hungary, 2Institute of Nuclear
Research of The Hungarian Academic Sciences, Debrecen, Hungary, 3Mediso Ltd.,
Budapest, Hungary
Background: The examination of small animals using high resolution in vivo imag-
ing methods is a crucial tool in pharmaceutical research projects. Too suffice this
demand, a full ring small animal PET camera (MiniPET-II) has been built in our
Institute as part of succesive R+D projects.
The aim of the study was to develop a complete hardware and software system
supporting 3D PET-data acquisition, image reconstruction, image processing and
evaluating the performance parameters of this scanner according to the guidelines
of National Electrical Manufacturers Associations (NEMA) NU-4 standards.
Material and methods: The fully modular MiniPet-II scanner consists of 12 detector
modules in a single ring with LySO scintillator crystal blocks and position sensitive
PNTs. Each crystal block comprises 35 ¥ 35 pins of 1.27 ¥ 1.27 ¥ 12 mm size.
Detector signals are processed by FPGA based digital signal processing boards
with embedded Linux operating system.
Results: Using cluster technique we have implemented a network based data aqui-
sition system comprising embedded Linux environment of the detectors and data
aquisition computer. A signal processing software controls the processing of the
primary data. To support the image reconstruction, software was developed capa-
ble of running either on multi-core computers, clusters and computers equipped
with graphical processing units as mathematical co-processors. Performance pa-
rameters were evaluated by NU-4 protocols.
Conclusion: Based on the successful performance test measurements and the first
biological studies the MiniPET-II scanner is an appropriate in vivo imaging tool sup-
porting small laboratory animal investigations.
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DEVELOPMENT AND ERROR-ANALYSIS OF SINOGRAM CORRECTION
METHODS FOR MINIPET-II
Gy. Kovács, G. Opposits, S.A. Kis, L. Balkay, L. Trón, M. Emri
Institute of Nuclear Medicine, University of Debrecen, Hungary
Background: The examination of small animals using high resolution in-vivo imag-
ing methods is a crucial tool in pharmaceutical research projects. To suffice this
demand, a small animal PET camera has been developed in our institute as part of
a R+D project. The implementation of image reconstruction components was an
important part of the development. In order to reduce the high time- and computa-
tion-demand of the full 3D reconstruction, data acquired in 3 dimensions have to
be separated into 2D slices (rebinning) followed by 2D filtered backprojection (FBP)
and iterative reconstruction algorithms. Our detector system is polygonally shaped,
thus the sinograms we use for 2D reconstruction are not continuous, which may
interfere with the reconstruction process.
The aim of the study was the adaptation and analysis of the methods for the estima-
tion of missing data in the sinograms of polygonal detector systems, and the elabo-
pration of a new method based on special segmentation techniques.
Results: We succeeded in working out a new mathematical algorithm to generate
the missing data used during image reconstruction. This method was compared to
3 conventional procedures using real and simulated data. The traditional single
slice method was used for the rebinning followed by the FBP and ML-EM image
reconstruction algorithms. The comparison was carried out applying profile curve
and ROI analysis.
Conclusions: The performed tests revealed that our method provides results simi-
lar to those by conventional methods and, at the same time, it has the benefit of
having lower noise sensitivity.
INTERRELATIONSHIP BETWEEN ACQUISITION TIME AND LESION
DETECTABILITY BY TIME-OF-FLIGHT PET/CT CAMERA
L. Balkay1, Zs. Hascsi2, I. Garai2, L. Trón1, M. Emri1, E. Hevesi1, L. Galuska1
1Institute of Nuclear Medicine, University of Debrecen, Hungary, 2PET-CT Ltd., Debrecen,
Hungary
Background: Lesion detectability depends on several factors such as the amount
of the injected pharmaceutical,  body/mass index (BMI),  acquisition time per bed
position (ATB), lesion to background accumulation ratio (T/B ratio), etc. With TOF
PET cameras ATB is usually about 1 minute but only limited information is available
how the image quality changes using different timing.
Material and methods: The studies were carried out on Philips Gemini TF 64 PET/
/CT camera. Images belonging to 10, 30, 60, 90, 120, 150 and 180 sec exposition
times were reconstructed from list mode stored data and further analysed by visual-
ization software of the manufacturer and a  Matlab program.
Results: Analysis has shown that small lesions (£ 4 mm) with T/B ≥ 5 are easily
detectable using as short as 30 sec data acquisition. Larger lesions (≥ 4 mm) of
similar accumulation ratios can be visualized even in 10 sec ATB. However, if T/B =
2–4 (e.g. lesion next to the liver), detection requires longer acquisition time (ATB =
1–3 min.)
Conclusions: Setting acquisition time belonging to different tissue regions in
a way as detailed above, total scan time may be much shorter compared to the
10.15 min standard. Under these conditions good quality images and standard
examination time can be achieved by using less than the usual FDG dose. This
could result in a decreased radiation dose and decreased radiopharmaceutical
demand.
NOVEL OPPORTUNITIES IN NUCLEAR MEDICINE PROVIDED
BY THE INTERNET
A. Székely
Faculty of Medicine, University of Debrecen, Hungary, 6th year
Background: The birth of Web 2.0 opened a new chapter in the history of the Inter-
net. Since 2004, a large number of services have been developed which emphasize
collaboration, communication and creativity. Facilities provided by this “social Web”
may be utilized in higher education and patient education. To examine these op-
portunities, we founded our diagnostic imaging blog, called Tomographyblog.com,
in 2007. Later, we developed a search page and a community portal.
Material and methods: We registered our blog with a free service provider, and
since then we have been informing our audience about the latest in diagnostic
imaging. We hosted a four-week educational quiz in partnership with the Univer-
sity of Debrecen Nuclear Medicine Department during the Fall semester of 2007/
/2008. Our search page, SeekRadiology.com, puts all the relevant search engines
in diagnostic imaging on an easy-to-use webpage. Our community site,
NuklearisMedicina.hu, aims to provide information for patients and to facilitate
learning, but it also offers content for professionals.
Results: Our blog is one of the most popular diagnostic imaging blogs with over
7000 visitors per month. The quiz got 561 visitors and 26 students sent in answers
at least once. Traffic on SeekRadiology.com is around 150 per day, while
NuklearisMedicina.hu is currently in beta testing.
Conclusion: Web 2.0 may facilitate medical education and it can help improve the
efficiency of patient education as well. These opportunities may be employed in
any area of medicine, but it is vital that doctors and other experts create this con-
tent.
GPU TECHNOLOGY IN MEDICAL IMAGING
I. Lévay, M. Koselák, S.A. Kis, G. Opposits, L. Trón, M. Emri
Institute of Nuclear Medicine, University of Debrecen, Hungary
Background: R&D projects by the Institute of Nuclear Medicine of the University of
Debrecen comprise the development of PET-related data acquisition, image recon-
struction, image processing software libraries, and test applications. An important
task of this kind is to study how the 2D–3D image reconstruction, noise-reduction,
and image registration methods can be implemented on HPC platforms. The appli-
cation of a graphics processing unit as multiprocessor system is one of the most
important HPC solutions, because GPU's computational performance is 2 orders of
magnitude larger than that of CPU.
The aim of the study was to develop special software components running on GPU
hardware, significantly reducing the processing time of common 2D–3D iterative
image reconstruction, 3D image filtering, manipulation, and image registration al-
gorithms.
Results: The developed components are part of a larger multimodal imaging pack-
age developed by our institute. The easy to use and well scalable nVIDIA’s hard-
ware and CUDA software architecture have been used, because they have remark-
ably good price/value ratio. Our results affect three image processing areas. The
new PET-reconstruction component allows a reduction by factor of 8 the recon-
struction runtime as compared to the conventional, CPU-based solutions. The run-
ning time of GPU directed image manipulation and most of the 3D image filter
algorithms were ~300 times faster than the same operations by an average com-
puter, without GPU support. The cost-function calculation of the automatic image
registration has been successfully improved.
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KIT-FORMULATED THERAPEUTIC RADIOPHARMACEUTICALS
J. Környei, L. Baranyai, V. Horváth, D. Makai, Z. Bíró, M. Paál
Institute of Isotopes Co. Ltd., Budapest, Hungary
Background: The aim of the kit formulation is to perform ‘on-the-spot’ radiolabel-
ling reactions, providing immediate use of therapeutic agents. Two kit-formulated
active substances, EDTMP and sodium phytate, were investigated using various
radionuclides.
Material and methods: Active substances were preapred according to GMP. 90Y,
153Sm, 165Dy, 166Ho, 169Er, 177Lu were used as labelling radionuclides. Radiochemi-
cal purity was measured by radio-TLC methods. The particle size limit of suspen-
sions was determined by filtering.
Results:
1. Kit-formulated EDTMP: The kit, if stored in a refrigerator, is stable for 36 months.
Higher than 98% labelling efficiency could be achieved using 90Y, 153Sm or even
177Lu. The radiochemical purity of labelled 90Y- and 153Sm-EDTMP, stored at ambi-
ent temperature, is higher than 95% after 24 hrs, while 177Lu-EDTMP is stable at
ambient temperature for 30 days. The stability of radioactive complexes obtained
by labelling the kit-formulated EDTMP are significantly higher than that of the ready-
made 153Sm-EDTMP.
2. Kit-formulated phytate: Radiocolloids of a particle size of 0.2–1.5 mm were ob-
tained within 1 hour. The radiochemical purity of phytates exceeded 98 % and 95%,
just after labelling and within 3 hrs, respectively. Leakage values of 90Y-, 165Dy,
166Ho- and 169Er-phytate from rabbit knee after 2 hrs p.i. were 1.8; 0.9; 1.2 and 1.3%,
respectively. Leakage of 166Ho-holmium phytate in humans was found lower than
0.72% after 3 days.
Conclusions: Although the application of the kits requires more care and work in
the hospital's hot lab, kit formulation can be considered rather a promising ap-
proach than a blind path.
RADIOPHARMACEUTICALS
AN ALTERNATIVE METHOD FOR ALIPHATIC NUCLEOPHILIC RADIOFLU-
ORINATION
I. Kertész, I. Jószai, L. Galuska
Institute of Nuclear Medicine, Medical and Health Science Center, University of Debrecen,
Hungary
Background: Aliphatic nucleophilic substitution with [18F]fluoride ion can be high-
ly efficient; and under favourable circumstances yields may be quantitative. These
reactions are usually performed in a polar aprotic solvent such as acetonitrile, DMSO,
etc. Despite the good reactivity of anhydrous [18F]fluoride in this medium , the method
has some drawbacks. Fluoride can cause the elimination of alkyl halides or alkyl
sulfonates to alkenes, and hydroxylation can occur to alcohols because “naked”
fluoride can act not only as a nucleophile but also as a base. In general, as the
dryness and therefore nucleophilicity of the [18F]fluoride ion increases, there is an
increasing tendency for its adsorption onto reaction vessel walls, which decreases
the overall radiochemical yield.
It has been reported that ionic liquids containing imidazolium cations can act as
powerful media in some catalytic organic reactions to accelerate reaction rate and
improve selectivity. Recently, it was reported that tert-alcohol solvents show good
performance in nucleophilic fluorination, allowing side reactions to be remarkably
suppressed via a weak F-H hydrogen bond, which maintains the inherent nucleo-
philicity but reduces the basicity of the fluoride. More recently a synergistic effect in
nucleophilic fluorination was demonstrated when ionic liquid and tert-alcohol were
combined into one molecule.
Material and methods: We have synthesised a combined catalyst molecule
(1-(2-hydroxy-2-methyl-n-propyl)-3-methylimidazolium mesylate, and tested it in
some aliphatic nucleophilic substitutions.
Results and conclusions: We have demonstrated the viability of the new concept,
but we need an extensive optimisation of this method to develop it into a competi-
tive alternative of the current radiofluorination.
SYNTHESIS OF L-[METHYL-11C] METHIONINE FOR HUMAN DIAGNOSTIC
PURPOSES
T. Miklovicz, B. Rubleczky, I. Jószai, Z. Fodor, L. Trón, L. Galuska, P. Mikecz
Medical and Health Science Center, Nuclear Medicine Center, University of Debrecen,
Hungary
Background: L-[methyl-11C]methionine (MET) is a useful aminoacidic tracer for the
diagnosis of brain tumors. Most brain tumor examinations are based on MET, found
to be more accurate in imaging the extent of brain tumors than FDG and conven-
tional CT. PET examinations were carried out between 1997 and 2004 in Hungary
with MET produced by the Institute of Nuclear Research. Moving of the PET Centre
to a new building necessitated the development of a fast, high-yield, automatic
synthesis method.
Material and methods: For the production of MET we use materials suitable to
GMP, if possible pharmacopoeia quality. The 11CO2 content of the irradiated target
gas is first converted into 11C-methyl iodide in a gas phase reaction. In the new
synthesis module using sterile, disposable syringes and tubing 11C-methyl iodide
was converted into MET. Due to the catalyst, we only get L-form without any byprod-
uct. We obtain the isotonic concentration by adding physiological saline and puri-
fying the product on SPE cartridges. The QC and the release of the product take
place according to the European Pharmacopoeia.
Results: 5 minutes after the 11C-methyl iodide gas phase synthesis (12 minutes)
purified MET is obtained in an isotonic solution. After 20 minutes' bombard-
ment (30 µA) 3594 ± 1464 MBq MET is synthesized (n = 5). The QC found 100%
enantiomeric purity, > 99% radiochemical purity and 100% radionuclidic purity.
Our institute has recently obtained the Marketing Authorization of the
L-[methyl-11C]methionine (MET-PET injection).
Conclusions: Since March 2009, the human diagnostic PET investigation of brain
tumors has been re-set in Debrecen, using the MET-PET injection produced by our
institute.
ASCORBIC ACID STABILIZER EFFECT TO REDUCE RADIOLYTIC FDG
DECOMPOSITION
P. Németh1, L.Colmenter2, L. Sajo-Bohus1, H. Barros1, E.D. Greaves1
1Laboratory of Radiopharmacy, University Simón Bolívar, Caracas, Venezuela,
2Diagnostic Centre CCD, Caracas, Venezuela
The 2-deoxy-2-[18F]fluoro-D-glucose (FDG) has been  widely used in nuclear med-
icine for diagnostic studies with positron emission tomography (PET). Due to the
relatively short (109 min) half-life of the 18F isotope, this compound has to be pro-
duced in large quantities, at high radioactivity concentration. Usually the initially
prepared radioactivity concentrations of FDG are 10 to 50 times higher than actually
required at the time of administration. The decomposition of radiopharmaceuticals
depends on high levels of radioactivity and specific activity.  FDG becomes unsta-
ble in highly radioactive solutions and alkaline pH and at higher temperatures. The
ionizing radiation emitted from the 18F isotope in water solvent and air makes hydro-
gen peroxide accelerate the FDG decomposition rate and therefore shortens the
useful shelf life of the radiopharmaceutical.  The objective of our study is to monitor
the degradation of FDG at various radioactive concentrations by determining radi-
ochemical purity at different time intervals, and to assess the effects of ascorbic
acid as a stabilizer for FDG preparation. The results of the study show that the
ascorbic acid as antioxidant agent is an effective stabilizer.
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DETERMINATION OF TUMOR SIZE AND PERFUSION AS IN VIVO
BIOMARKER IN THE TREATMENT OF MOUSE TUMOR MODELS
D. Máthé1, 2, G. Németh2, L. Balogh1, A. Polyák1, Gy.A. Jánoki1
1National “FJC” Research Institute for Radiobiology and Radiohygiene, Budapest,
Hungary, 2Mediso Ltd., Budapest, Hungary
Background: We examined the possibilities of monitoring lesion size and blood
perfusion as biomarkers for mouse tumor model treatments. We decided to use
quantification of uptake and size as marker of perfusion.
Material and methods: Studies have been performed using the dedicated multi-
plexed multipinhole SPECT/CT small animal imager. 10 MBq of 99mTc-protein col-
loid (Nano-Albumon) was injected intravenously for 6 SCID mice implanted with
hepatoma cells in the spleen metastatizing to the liver. For CT scans, eXiaTM was
used as a liver agent. SPECT/CT scans were made 3h post injections. Subcutane-
ous tumor models were represented by 3 ¥ 5 mice with subcutaneous melanoma
with two types of treatment, erythropoietin plus Avastin (E + A) or Avastin (A) alone.
Animals were scanned at start and 1 week post start of therapy. Hepatomas were
treated with a proprietary derivative of Avastin. Tumor perfusion was defined as
absolute activity content in the tumor compared to one part of the (clearly identi-
fied) aorta.
Results: In all mice metastatic liver tumor foci were visualized as cold spots while
CT identified the contrast-enhancement in all lesions. We could not find significant
difference between tumor size reduction in E + A and A treatments that however in
turn differed significantly from untreated control.
Discussion: Multiplexed multipinhole helical SPECT is an excellent tool to perform
in and ex vivo non invasive studies in small animals. This method allowed accurate
identification of in vivo biomarkers of a model for further therapy screening.
SCINTIGRAPHIC DETECTION OF SPLENIC TISSUE AFTER SPLEEN
PRESERVING SURGICAL TECHNIQUES IN CANINE MODEL
J. Varga1, I. Furka2, E. Sajtos2, Z. Fodor1, F. Kiss2, T. Nagy1, K. Petö2, L. Galuska1,
I. Mikó2
1Department of Nuclear Medicine University of Debrecen, Hungary, 2Department
of Operative Techniques and Surgical Research, University of Debrecen, Hungary
Background: Spleen preserving techniques performed for the surgical treatment of
traumatized spleen may prevent serious postoperative complications, such as Over-
whelming Postsplenectomy Infection (OPSI) Syndrome or Disseminated Intravas-
cular Coagulation (DIC). Investigation into the restoration of splenic function could
help in human clinical practice to find non-invasive methods for the detection of
possible hyposplenic-asplenic states/conditions. We tested whether scintigraphy
with denatured red blood cells (RBCs) is suitable for the detection of functioning
splenic tissue in beagle dogs.
Material and methods: Tc-99m labeled RBCs were denatured by stannous chlo-
ride and heat treatment was adapted for dogs. The efficiency of the imaging meth-
od was tested in six groups: whole spleen was retained (sham-operated) or re-
moved (splenectomy) (n = 1–1), 1/3 or 2/3 part of the spleen was resected
(n = 2–2), 5 or 10 spleen-chips were reinserted into the greater omentum by Furka's
method following splenectomy (n = 2–2).
Images by a two-headed gamma camera were started with dynamic series simulta-
neously from anterior and left lateral views, then SPECT acquisition followed. From
the dynamic series parametric images of change rate were calculated. Tomograph-
ic images reconstructed using OS-EM algorithm were attenuation-corrected using
Chang's method, and the total uptakes of foci accumulating radiopharmaceutical
were expressed as fractions of injected dose.
Results: The parametric images of animals showed that the scintigraphic method
specifically visualized splenic tissue (where activity increased with time). 77% of
autotransplanted spleen-chips were visualized with varying uptake values.
Conclusion: Scintigraphy with labeled denatured RBCs proved to be capable of
detectingfunctioning splenic tissue in a non-invasive way.
Grants: OTKA T-049331, ETT 387/2006.
CHROMATOGRAPHIC AND BIOLOGICAL ANALYSIS OF 99MTC-SESTAMIBI
PREPARATIONS
G. Jánoki1, A. Polyák2, L. Balogh2, Gy. A. Jánoki3, L. Körösi3
1Radiopharmacy Laboratories Ltd., Budaörs, Hungary 2National “FJC” Research Institute
for Radiobiology and Radiohygiene, Budapest, Hungary, 3Medi-Radiopharma Ltd., Érd,
Hungary
Background: Our aim was to compare the impurity profiles of various 99mTc-sesta-
mibi preparations by using radio-HPLC, radio-TLC, radio-PC and the cardiac up-
take evaluated in rats.
Material and methods: We used the current European Pharmacopoeia methods
and the European Pharmacopoeia reference standard for comparison of various
99mTc-sestamibi preparations. The following compounds were evaluated: Cardio-
lite®, Medi-MIBI 500 micrograms, CARDIO-SPECT, TechneScan Sestamibi, Euro-
pean Pharmacopoeia reference standard: Sestamibi Labelling Kit CRS. All the kits
were labeled according to their instructions. In rats, the standard biodistribution
was evaluated. All the chromatographic evaluations were focused to determine the
three main impurities having a given limit value in the European Pharmacopoeia.
For impurity A ([99mTc]O4
–) radio-TLC, radio-HPLC, for impurity B (99mTc in colloidal
form) radio-TLC, radio-PC and for impurity C ((OC-6-22)-pentakis[1-(isocyano-kC)-
-2-methoxy-2-methylpropane][1-( isocyano-kC)-2-methylprop-1-ene]
[99mTc]technetium (1+)) radio-HPLC were used. The radiochemical purity
(99mTc-Sestamibi) was estimated from the results of the three different chromato-
graphic methods.
Results: All the studied products have radiochemical purity above the European
Pharmacopoeia limit value (minimum 94%). However the impurity profiles showed
differences concerning the amount of impurity C. Cardiac uptake in rats ranged
between 1.2–2.0% of injected dose.
Conclusion: Different radio-chromatographic methods (especially radio-HPLC)
combined with biodistribution studies provide adequate information about the im-
purity profile and the required pharmaceutical quality of various 99mTc-sestamibi
preparations used daily in the nuclear medicine practice. In our experience, these
widely used methods are also useful in the development of new radiopharmaceuti-
cals.
Acknowledgment: This work was partially sponsored by the New Hungary Deve-
lopment Plan supported by the European Union.
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PRECLINICAL STUDIES
DRUG INTERACTIONS, TOXICITY DATA AND FEASIBILITY ASPECTS
OF SPECT/CT EXAMINATIONS IN DOGS
L. Balogh1, L. Seres2, G. Nemeth2, J. Thuroczy3, D. Mathe1, A. Polyak1, T. Koncz1,
G. Andocs1, P. Chaudhari4, G. Janoki5, Gy.A. Janoki5
1National “FJC” Research Institute for Radiobiology and Radiohygiene, Budapest,
Hungary, 2Mediso Ltd., Budapest, Hungary, 3Veterinary Faculty, Szt. Istvan University,
Budapest, Hungary, 4Advanced Center for Treatment, Research and Education in
Cancer, Mumbai, India, 5Medi-Radiopharma Ltd., Radiopharmacy Ltd., Budapest,
Hungary
Background: Combining the advantages of morphological and functional imaging
the so called fusion (or hybrid) imaging is a novel diagnostic tool in more devel-
oped human oncological centers. The same technique and instrumentation is the-
oretically very useful in localizing, staging and following-up canine oncological
cases as well. Only few data exist currently whether or not rapid intravenous injec-
tions (e.g.intravenous anaesthetics, intravascular contrast agents and radiophar-
maceuticals)  haveany interactions, side effects or limitations of  detection during
an intervention.
Material and methods: Client-owned dogs, altogether 18, were referred to SPECT/
/CT examination at our Institute, with different known malignant diseases.  The dogs
were sedated (propofol and diazepam iv), and injected with different radiopharma-
ceuticals 20–50 MBq/10 bwkg (99mTc-MIBI, 99mTc-DMSA(5), 99mTc-MDP, Medi-Ra-
diopharma Ltd., Hungary). All the dogs were also given intravascular contrast agent
in a dose of 0.5 g iodine/bwkg (Iomeron, Bracco, Milan, Italy). Fusion images were
taken, evaluated and before and, immediately after data acquisition, haematologi-
cal and biochemical parameters were checked.
Results: During and after the examinations, no unusual clinical signs were ob-
served and no significant changes were detected between the blood parameters.
All the 18 dogs tolerated the procedure well and the required data were ready for
analysis. No chemical and in vivo interactions were recognized during the proce-
dure.
Conclusions: Based on the above it can be concluded that the novel type of SPECT/
/CT hybrid imaging is feasible in dog patients. This diagnostic imaging technique
is harmless and provides important information for veterinary oncologists as well.
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RENAL CAPSULE PARATHYMIC LYMPH NODE COMPLEX: IMAGING
OF A NEW IN VIVO METASTATIC MODEL IN RATS WITH 18F-FDG
Gy. Trencsenyi1, P. Kertai2, F. Bako1, J. Hunyadi3, T. Marian1, S.A. Kis1,
G. Opposits1, M. Emri1, I. Pocsi4, G. Banfalvi4
1Department of Nuclear Medicine, University of Debrecen, Hungary, 2Department
of Preventive Medicine and Public Health, University of Debrecen, Hungary, 3Department
of Dermatology, University of Debrecen, Hungary, 4Department of Microbial
Biotechnology and Cell Biology, University of Debrecen, Hungary
Background: In our experiments, we wished to prove — using mini-PET, autora-
diography and organ distribution examinations — that rat hepatocarcinoma
(He/De), and mesoblastic nephroma (Ne/De) cells give metastases to the parathy-
mic lymph nodes.
Material and methods: 106 He/De or Ne/De cells were placed under the capsule of
the left kidney. Two weeks after implantation, control and tumor-bearing rats were
anesthetized and a radioligand, 18FDG (15.0 MBq), was injected i.v. For autorad-
iography, 60 µm thick cryostate sections (Leica cryomacrotome) were cut and ex-
posed to phosphor imaging plates. Results were expressed in intensity pixel units.
For organ-distribution, different tissues were removed and their activities were mea-
sured. The radioactivity of the samples was used to determine the differential ab-
sorption ratio (DAR).
Results: By taking the pixel density of resting striated muscle as one unit, the rela-
tive pixel densities were in decreasing order: 14.23 in He/De tumor, 10.82 in par-
athymic lymph nodes, 5.36 in kidney, 2.35 in blood and 1.57 in liver. In the case of
the Ne/De, the results were the same. The DAR values also showed that the majority
of the radioactivity was accumulated in the tumors and in the parathymic lymph
nodes.
Conclusions: From the autoradiographic, phosphor image and tissue distribution
experiments, we concluded that He/De and Ne/De tumors grown under the cap-
sule of kidney represent a significant metastatic burden manifested primarily in
parathymic lymph nodes. The renal capsule and parathymic lymph node complex
seems to be suitable for the isolated in vivo examination of metastatic development
and for the detailed analysis of secondary tumors.
SIGNIFICANCE OF SPECT/CT IMAGING IN THE SPECIFIC METHODS
OF NUCLEAR ONCOLOGY
K. Zámbó, Zs. Szabó, S. Szekeres, M. Sarkadi, E. Schmidt
Department of Nuclear Medicine, University of Pécs, Hungary
Background: There are many specific methods in nuclear medicine to verify the
different tumors on the basis of metabolic changes, hormonal synthesis or recep-
tors overexpressed on the surface of tumor cells. Does fusion imaging give more
information in that case?
Material and methods: Scintigraphy completed by SPECT is a tomographic tech-
nique to image local radioactive tracer distribution in tumor tissue to indicate func-
tional changes. In the case of specific binding of radiopharmaceuticals to the tu-
mor cells, very few other structures are seen in the picture.  Multimodality equip-
ment (SPECT/CT, PET/CT) is used to try and solve this problem.
Results: This presentation reports about almost 2 years of experience with the first
Hungarian multislice SPECT/CT (DHV/CT, Mediso). We evaluated  the  exact local-
ization of parathyroid adenomas (93), somatostatin receptor content of the lung
and GEP tumors (48), adrenergic receptor density of neuroendocrine tumors (23 131I-
MIBG + 20 123I-MIBG), iodine accumulation of the remnant and metastases of thy-
roid cancer after high-dose 131I treatment (102). Some studies have demonstrated
that the information obtained by SPECT/CT is more accurate in evaluating patients
than the ones obtained from either SPECT or CT alone.
Conclusion: SPECT/CT systems provide both the functional information from SPECT
and the anatomical information from CT in a fusion examination, which increases
the success of the therapy. It plays a very important role in the differential diagnosis
of the tumors and the improvement of the specificity of methods in nuclear medi-
cine.
THE SIGNIFICANCE OF SPECT/CT IN THE DIAGNOSIS
OF PARATHYROID ADENOMAS
E. Schmidt1, Zs. Szabó1, K. Dérczy2, Cs. Weninger2, S. Szekeres1, M. Sarkadi1,
K. Zámbó1
1Department of Nuclear Medicine, University of Pécs, Hungary, 2Department
of Radiology, University of Pécs, Hungary
Background: The aim of our study was to determine the role of  99mTc-pertechnetat
and 99mTc-MIBI scintigraphy using planar, subtracted, SPECT and SPECT/CT scans
in the diagnosis and localisation of parathyroid adenomas.
Material and methods: 50 hyperparathyroid patients were observed. Fifteen and
120 minutes after the injection of 370 MBq 99mTc-MIBI, planar scans of the neck
and mediastinum were performed, with subtraction (99mTc-MIBI/99mTc-pertech-
netat) in both phases, and 90 minutes after the injection with the completion of
SPECT/CT examination.
Results: In 22 cases planar, subtracted, SPECT and SPECT/CT scans were posi-
tive. In 10 patients, parathyroid adenomas were successfully extracted and proved
by histology. Nineteen cases were negative in all examinations. Even so, 1 patient
was operated on and histology did not find parathyroid tissue. Besides the negativ-
ity of planar and subtracted scans, SPECT and SPECT/CT examinations were pos-
itive in 5 cases. In 1 case, the SPECT image was positive besides the negativity of
planar and subtracted scans, but SPECT/CT did not show adenoma in the location
of increased cumulation. In 2 patients, on the basis of suspect planar and subtract-
ed scans, SPECT and SPECT/CT and successful operation confirmed the diagno-
sis in 1 case, but in the other one SPECT and SPECT/CT did not support the initial
diagnosis. In 1 case, besides the positivity of planar and subtracted scans, SPECT
and SPECT/CT were negative.
Conclusions: In addition to planar and subtracted scans, a SPECT image increas-
es the specificity and sensitivity of the method but accurate localisation, insured by
SPECT/CT, is the key to a successful operation.
COMPARISON OF TL-201 AND NITROGLYCERIN-AUGMENTED T
K. Buga1, M. Moravszki1, K.Bus2, M. Tóth1, I. Szilvasi1
1 Deptartment of Nuclear Medicine, State Health Centre, Budapest, Hungary,
2Department of Nuclear Medicine, Semmelweis University, Budapest, Hungary
Background: Tl-201 and nitroglycerin-augmented Tc-99m-tetrofosmin scintigraphy
(Ngl-TF) are used for rest myocardial perfusion scintigraphy (MPS) to evaluate my-
ocardial viability in patients with ischaemic heart disease (IHD) and fixed perfusion
defects on stress MPS. Our aim was to compare the results of rest MPS using Tl-201
and Ngl-TF by quantitative myocardial SPECT.
Material and methods: 47 patients (12 female, 35 male, median age: 636 ± 32
years) with angiographic evidence of IHD and fixed perfusion defects on ergomet-
ric stress MPS were enrolled in the study. Rest MPS with Tl-201 and rest Ngl-TF
were performed within two weeks using a dual-head SPECT system and quantita-
tive analysis (Emory Tool Box, 17-segments model, 5-point score system, normal
database).
Results: We analysed 799 segments, 411 (51.4 %) of which had normal uptake on
both scintigraphy, 252 (31.6%) had decreased uptake of both radiopharmaceuti-
cals. In 136 cases, (17.0%), segments uptake of Tl-201 and TF were different,
91 segments (11.4%) had normal Tl-201 but decreased TF uptake. The number of
segments with abnormal Tl-201 but normal TF uptake was 45 (5.6%). However, the
mean severity of perfusion defects of Tl-201 and TF did not differ significantly (1.78
and 1.81 respectively). Discrepancies in the uptake of the two radiopharmaceuti-
cals were significantly more frequent in the anteroseptal region.
Conclusion: The extent of perfusion defects on resting Ngl-TF is larger than that on
Tl-201 scintigraphy. Tl-201 seems to be more sensitive in detecting viable myocar-
dial segments. The follow-up of these patients after revascularization is needed to
evaluate clinical relevance of our observation.
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DIAGNOSTIC USEFULNESS OF QUANTITATIVE ECG-GATED
MYOCARDIAL PERFUSION SCINTIGRAPHY IN ISCHEMIC HEART DISEASE
M. Moravszki, K. Buga, M. Tóth, I. Szilvási
Department of Nuclear Medicine, State Health Centre, Budapest, Hungary
Background: The aim of our study was to evaluate the usefulness of the quantita-
tive resting ECG-gated SPECT (R-gSPECT) in stress myocardial perfusion scintig-
raphy (MPS) to diagnose ischemic heart disease (IHD).
Material and methods: 30 patients with IHD were studied. The patients underwent
coronary angiography (CAG) within two months. Stress-rest MPS with R-gSPECT
was performed (one-day protocol, 500 + 900 MBq Tc-99m-tetrofosmin, GE-Infinia-
Xeleris). Emory Cardiac ToolBox and QPS/QGS (Cedars-Sinai) programs were used
for quantitative evaluation. Perfusion, motion (M) and systolic thickening (T) of the
510 myocardial segments (17-segments model) were evaluated quantitatively with
score-systems.
Results: 298 segments had normal perfusion, 121 segments had reversible, and 91
had fixed perfusion defects. In 298 segments with normal perfusion, decreased M
was found in 32 (10.7%), decreased T in 16 (5.3%) cases. These abnormalities were
moderate; two-thirds of them were located in the septal region. From 121 ischemic
segments 19 (15.7%) showed decreased M, and 17 (14.0%) decreased T. In 91
segments with fixed perfusion defect 52 (57.1%) had decreased M and 40 (44.0%)
decreased T. The frequencies of decreased M and T were higher in segments with
severe perfusion defect (73.3% and 66.6%, respectively).
Conclusions: Quantitative R-gSPECT improves the accuracy of MPS. Based on
comparison to CAG, it decreases the number of false-negative findings, and signif-
icantly decreases false-positive diagnoses of IHD caused by attenuation. It may
detect stress-induced myocardial stunning. In the evaluation of M and T of the
septum, R-gSPECT is less reliable. M analysis is more sensitive, T analysis is more
specific in detecting regional left-ventricular dysfunction.
DIAGNOSTIC USEFULNESS OF EARLY GATED MYOCARDIAL
PERFUSION SPECT
M. Tóth1, M. Moravszki1, K. Buga1, R.G. Kiss2, I. Szilvási1
1Department of Nuclear Medicine, State Health Centre, Budapest, Hungary, 2Department
of Cardiology, State Health Centre, Budapest, Hungary
Background: ECG-gated myocardial perfusion SPECT (GSPECT) gives simulta-
neous information on myocardial perfusion and global/regional left-ventricular (LV)
function in ischemic heart disease (IHD). Ergometric stress can provoke myocar-
dial stunning. We studied the usefulness of early GSPECT (15-G: 15-minutes after
exercise) compared to standard GSPECT (60-G: 60-minutes after exercise) in de-
tecting exercise-induced reversible LV dysfunction.
Material and methods: Twenty three patients with IHD were studied. Six had de-
creased, 17 had normal LV-EF at rest. We performed 15-G, 60-G and resting GSPECT
(R-G). LV-EF, segmental wall-motion and systolic wall-thickening of the three ex-
aminations were compared using QPS/QGS-program.
Results: Out of the 6 patients with low EF at rest, EF was decreased by 15-G in 5,
and by 60-G in 3. Of the 17 patients with normal EF, decreased EF was found in 3
by 15-G and 60-G as well. The decrease was more prominent by 15-G.
In segments with normal perfusion (n = 220), no significant changes of motion/
thickening were found. By 15-G decreasing motion in 23%, decreasing wall-thick-
ening in 19% of the segments with ischemia (n = 105) were found — compared to
60-G and R-G as well. In segments with fix perfusion defect (n = 52) further de-
crease of thickening was found in 25% by 15-G and in 6% by 60-G. (14 segments
with “inverse redistribution” were not analyzed).
Conclusions: 15-G is useful in detecting exercise-induced LV-dysfunction. It de-
tects transient decrease of LV-EF more frequently than by 60-G. Worsening of seg-
mental motion/thickening occurs in some ischemic segments. They can be detect-
ed by 15-G only. The deterioration of wall-thickening in segments with fixed perfu-
sion defect can be found more frequently by 15-G.
SIGNIFICANCE OF 99MTC-DTPA EYE SPECT IN PATIENT SELECTION
FOR ORBITAL IRRADIATION IN GRAVES' OPHTHALMOPATHY/
/ENDOCRINE ORBITOPATHY
L. Szabados1, E.V. Nagy2, B. Ujhelyi2, H. Urbancsek3, J. Varga4, L. Galuska4
1PET-CT Ltd., Debrecen, Hungary, 21st Department of Internal Medicine, University
of Debrecen, 3Department of Radiotherapy, University of Debrecen, Hungary,
4Department of Nuclear Medicine, University of Debrecen, Hungary
Background: Therapy remains without any obvious effect in a large proportion of
patients with endocrine orbitopathy (EOP). Those with active orbital inflammation
usually respond to treatment. Using the DTPA technique before and after irradia-
tion, we measured the inflammatory activity in the retrobulbar region to determine if
it was suitable for the selection of patients for this therapeutic modality.
Material and methods: Thirty-two patients with EOP treated with standard external
irradiation were included in this retrospective study (age 52.1 ± 11.0 years). Before
and within 12 weeks after irradiation, SPECTs were performed (400 MBq DTPA
Nucline Xring/4R). Beside visual assessment, the uptake values were calculated.
Based on disease-free orbits the upper normal uptake value, was 8 ± 1 ¥ 10–6/ml.
Results: Depending on the change in the DTPA uptake value after vs. before radio-
therapy, we assigned the patients into 3 groups: decreased, increased or did not
change. The initial DTPA uptake of these groups was significantly different. Im-
provement was observed only at higher initial values. Comparing the low (< 12)
and the high (≥ 12) initial uptake groups, an unexpected rise was observed in the
first group after therapy (+ 2.89), while the DTPA uptake decreased in the latter
group as expected.
Conclusion: In patients with initially normal DTPA uptake, irradiation had no effect.
In these patients, the inflammation might intensify, therefore, in their case, other
therapeutic measures should be considered. In contrast, an anti-inflammatory ef-
fect of irradiation with high uptake has been shown. The DTPA orbital SPECT is a
suitable technique in selecting patients with EOP for irradiation.
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MYOCARDIAL PERFUSION SPECT AND CORONARY CTA CUMULATIVE
EFFECT COMPARED TO "GOLD STANDARD" ICA
B. Kracskó, R. Kolozsvári, B. Mándi, I. Garai
1Department of Cardiology, University of Debrecen, Hungary, 2PET-CT Medical
Diagnostic Ltd., Debrecen, Hungary
Background: Myocardial perfusion SPECT has been one of the most accurate ex-
aminations in the diagnosis of ichaemic heart disease, but sometimes it has lead to
unjustified invasive coronary angiographies. 64-slice CT angiography (CTA) has
become a reliable diagnostic method of coronary artery disease, but it has also
resulted in false positive investigations.
Material and methods: We compared the CTA, SPECT and ICA findings of 30
patients (18 males, 12 females, mean age: 58 ± 9 years), who had undergone all of
the 3 examinations within 6 months. An important precondition was that CT and
SPECT preceded ICA. We applied a Phillips Brilliance PET/CT scanner for the CT
examination and we determined the coronary lumen using quantitative coronary
analysis. The coronary tree was dissolved on the basis of the 16-segment coronary
model. Narrowing of the coronary lumen by more than 50% was regarded to be
significant. Myocardial perfusion tests were carried out under dipyridamole load-
ing. The perfusion images were evaluated using Emory Tool Box Software. We de-
termined cumulative CTA and SPECT per segment sensitivity, specificity, and pos-
itive predictive and negative predictive values.
Result: Examining the two non-invasive methods together we found a significant
improvement of PPV, but due to the small sample, these results should be interpret-
ed with care. Since NPV is high in both CTA and SPECT, there was no significant
change in these values.
Conclusion: The two non-invasive methods, CTA and stress SPECT, can be suc-
cessfully combined to exclude false positive values, which can also help us to re-
duce the number of unjustified ICAs.
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DOPAMINE TRANSPORTER SPECT: 123I-FP-BETA-CIT
VS. 99MTC-TRODAT-1
Z. Besenyi1, M. Árgyelán3, Z. Szabó3, Z. Janka3, L. Pávics2
1Euromedic Diagnostics Ltd., Szeged, Hungary, 2Department of Nuclear Medicine,
University of Szeged, Hungary, 3Department of Psychiatry, University of Szeged,
Hungary
Background: Functional imaging with specific dopamine transporter ligands pro-
vides a marker for presynaptic neuronal degeneration. Striatal uptake correlates
with disease severity and monitoring of progression assists in clinical trials of po-
tential neuroprotective drugs. A comparative study was carried out on two presyn-
aptic dopamine transporter SPECT radioligands with a fast pharmacokinetic pro-
file, 123I-FP-beta-CIT (FP) and 99mTc-TRODAT-1 (TR), in order to assess their dif-
ferences of uptake.
Material and methods: We performed 30 123-FP-beta-CIT SPECT and within
4 days 99mTRODAT-1 SPECT, in the same subjects using the same standard im-
aging protocol. On the transversal reconstructed SPECT slices at the level of the
basal ganglia, regions of interest were fixed manually in the caudate head and
putamen separately; we used the occipital cortex as reference non-specific bind-
ing site. The binding potential was estimated by the ratio of the specific to non-
specific activity (C/O, P/O). The caudate/putamen ratio was also calculated (C/P).
Results: The mean binding potential with TR in the caudate and putamen was 1.57
(range: 1.45–1.65) and 1.52 (range: 1.45–1.60); with FP these values were signifi-
cantly higher 4.2 (range: 3.2–4.6) and 3.8 (range: 3.3–4.2). The overall correlation
between the two radiopharmaceuticals was significant but the values showed indi-
vidually large variation (Spearman's rank correlation overall: p = 0.0002, C/O:
p = 0.006, P/O: p = 0.0288, C/P: p > 0.5). The possible auses are: 1. small range
of uptake variations around the normal values (no real pathological data). 2. statis-
tical bias because of the low C/O, P/O values of TR.
Conclusion: 99mTc-TRODAT-1 is applicable but has a lower specific to non spe-
cific uptake ratio than 123I-FP-beta-CIT.
THE SIGNIFICANCE OF MYOCARDIAL PERFUSION SPECT IN TOLNA
COUNTY AND ITS PLACE IN IMAGE DIAGNOSTICS
I. Wágner, Á. Fetzerné Nácsa, L. Veigl
Department of Isotope Diagnostics, TMÖ Balassa János Hospital, Szekszárd, Hungary
Background: Based upon our study of Tolna county's statistical data of 2007, we
investigated into mortality having occurred in relation with ischemic heart disease.
Then we examined the diagnostic role of myocardial perfusion SPECT among the
diagnostic imaging techniques. If suspicion of cardiac disease arises, the first im-
aging technique to be chosen is ultrasound. This is followed by the myocardial
perfusion SPECT, which reflects the perfusion relations. The use of MRI and cardio
–CT is not yet spread in our region.
Material and methods: In 2007 we examined 560 patients (340 women, 220 men),
who underwent dipyridamol stress and rest myocardial perfusion SPECT with 99mTc-
MIBI and 201-TlCl. To determine myocardial viability we used the reinjection tech-
nique with the patient being in resting position.
Results: With the myocardial perfusion SPECT method, we detected ischemic heart
disease in 186 patients and myocardial infarction in13 patients. We performed my-
ocardial viability investigation using the 201-TlCl reinjection technique in 26 pa-
tients and we detected ischemia in 13 patients, and viability in 4 cases. In one
patient, the myocardial perfusion SPECT showed normal perfusion relations.
In 2007, the mortality figures in Tolna County were as follows: 801 ischemic heart
diseases, 754 tumours, 326 cerebral artery diseases, and 192 digestive system dis-
eases.
Conclusions: Ischaemic heart disease is the leading cause of death in Tolna County.
Our results prove that because of the national health significance of this disease, its
early detection is of great importance and myocardial perfusion SPECT has an out-
standing role in confirming the condition.
TECHNOLOGISTS' SESSION
PET-CT THROUGH THE EYES OF AN ASSISTANT
M. Árvai, A. Szerdahelyi, Zs. Lengyel, P. Molnár
Positron Diagnostic Center, Budapest, Hungary
Background: Positron emission tomography is a functional imaging procedure that
is capable of depicting the body's biochemical processes with the aid of molecules
marked with isotopes that radiate positrons. Today, PET imagers are integrated into
CT devices, making it possible to combine the functional images from the PET with
the morphological information from the CT in the same anatomical “slices” within
the context of one imaging.  The major advantage of PET/CT devices compared to
earlier diagnostic procedures is that, with their aid, even malignant lesions of a few
millimeters in size can be detected. PET/CT exams at the same time make it possi-
ble to avoid numerous other examination procedures, and therefore the path to
a precise diagnosis may be shortened and treatment can be quicker and more
effective.
Material and methods: With our presentation we would like to introduce this new
examination method, inform the general public/audience about its basis in physics
and follow the path the patient takes from admission, through the injection of the
isotope to the examination.
Results: The significance of PET-CT examinations is primarily in the area of oncol-
ogy, in staging, restaging and detecting reoccurrence.
Conclusions: In many cases, the examination results in the alteration of treatment.
This provides the patients with better chances for recovery.
THE ROLE OF PET-CT IN THE DIAGNOSIS AND TREATMENT
OF LYMPHOMA
N. Simon, E. Gecse, Zs. Lengyel
Positron Diagnostic Center, Budapest, Hungary
Background: By now, it has become part of the daily routine to request for a PET-
CT examination completed with diagnostic quality CT as a staging examination,
and PET-CT is the preferred method for restaging, too. The aim of this presentation
is to show the role of PET-CT imaging using IV X-ray contrast agents in the primary
staging of lymphomas, and introducing its indications and areas of utilization. The
authors will present the course of the examination and the advantages/disadvan-
tages of its use.
Material and methods: Since 2005, more than 4000 PET/CT examinations were
performed in the Pozitron Diagnostic Center for the staging or restaging of lympho-
ma patients. Only 1% of these scans was completed with diagnostic quality CT.
Results: Based on the fact that the injection of the IV contrast agent makes it possi-
ble to determine precisely the size of lymph nodes, it seems indispensable for PET/
CTs used in primary staging. This way PET/CT can entirely replace diagnostic CTs
utilized for this purpose. At the end of treatment, if the primary tumor has shrunk
and shown no FDG uptake, it can be considered as complete metabolic remission.
However, if the residual tissue was metabolically active, it might indicate the neces-
sity of further treatment. To demonstrate this phenomenon, the authors will present
a few cases.
Conclusion: In the future, FDG PET-CTs, performed with the injection of an IV X-ray
contrast agent, are expected to become more frequently used during the course of
primary staging for lymphomas and other malignant tumors.
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RADIO-IMMUNOTHERAPY OF NON-HODGKIN LYMPHOMA
AT THE NATIONAL INSTITUTE OF ONCOLOGY
P. Márkusné Szalai, L. Szám, I. Puskás, F. Garzó, F. Csoszánszki
National Institute of Oncology, Budapest, Hungary
Background: Zevalin therapy has been used in our hospital since 2005 in the treat-
ment of patients with non-Hodgkin's lymphoma.
Indications: Patients with recurrent or therapy resistant CD20+ B-cell non-Hodgkin's
lymphoma.
Purpose: “Cross fire” effect, the simultaneous treatment of all involved areas.
Methods:
— radio-immunotherapy;
— antigen: CD20;
— antibody: ibritumomab tiuxetan;
— isotope: Y-90.
Application: Zavalin was given after the second rituximab infusion as an ambulato-
ry injection.
Result: Radiation may kill even tumour cells with surface antigen density insuffi-
cient to bind an adequate quantity of antibodies. This kind of treatment does not
make the quality of life worse. Zevalin therapy may become an alternative and effec-
tive treatment for B-cell non-Hodgkin's lymphoma.
I-123-FP-CIT: BIOMARKER IN THE DIAGNOSIS OF PARKINSON’S
DISEASE — ROLE OF THE TECHNOLOGIST
M. Hoppál, S.Á. Janocsekné, E. Pinterics, H. Neuman
Department of Nuclear Medicine, Semmelweis University, Budapest, Hungary
Background: Dopamine transporter scintigraphy with I-123-FP-CIT reflects presyn-
aptic dopamine transporters in the striatum and it is a marker for dopaminergic
nigrostriatal neuron integrity. Therefore, it has been used in the differential diagno-
sis of Parkinson's disease and parkinsonism. Our aim was to summarize the task of
the technologist in performing an appropriate investigation.
Material and methods: Fourteen patients were studied. Informed consent of the
patients is needed. A detailed explanation of the investigation is important, be-
cause the cooperation of the patients is essential to avoid motion artefacts. The
thyroid uptake should be blocked by peroral iodine solution (or by perchlorate in
known iodine allergy). Three to six hours after an injection of 185 MBq of I-123-FP-
CIT i.v., SPECT is performed (LEHR collimator, 128 ¥ 128 matrix, energy peak: 159
KeV ± 10%, close proximity of the patient, circular rotation, 64 projections, recon-
struction with predefined programs, reorientation, software motion correction, if
needed).
Results: In all of our 14 patients good-quality I-123-FP-CIT scintigraphy was per-
formed.
Conclusions: The appropriate knowledge and skills of the technologist are the
prerequisites of investigating this special group of patients with motion disorders. A
good-quality scintigram results in a diagnostically useful scan, serving the interest
of the patient.
THE ROLE OF BONE SCINTIGRAPHY IN SELECTING PATIENTS
FOR VERTEBROPLASTY
T. Pásztor1, L. Molnár2
1Department of Nuclear Medicine, Gyula Kenézy Hospital, Debrecen, Hungary,
2Department of Traumatology and Hand Surgery, Medical and Health Science Center,
University of Debrecen, Hungary
Background: The aim of the study was to direct attention on the importance of
properly selecting patients for vertebroplasty.
Material and method: Radiography was the first examination in all of the patients
complaining of vertebral pain. Additional examinations mostly included CT and /or
MRI. If on the basis of the morphological image of the vertebrae vertebroplasty was
considered, we always performed bone scintigraphy (planar imaging and SPECT).
Vertebroplasty was only carried out if increased activity could be detected in the
corpus of the affected vertebra.
Results: Vertebroplasty was performed in 18 cases. (In 3 patients it was a second
intervention on another vertebra). Six patients had to undergo the operation due to
metastases, while in 12 patients the reason for surgery was compression fracture
due to osteoporosis. The pain diminished immediately after surgery and all of the
patients made long-term recovery.
Conclusion: The authors consider it necessary to perform bone scintigraphy in all
the cases of vertebroplasty because the intervention is only effective if the patients
are properly selected.
ONCOLOGY — THERAPY
SCIENTIFIC POSTERS
THE EXAMINATION OF THE EFFECTIVENESS OF RFA WITH PET/CT
Gy. Sándor, A. Szerdahelyi, M. Árvai, K. Kajáry, Sz. Szakáll, Z. Bánsághi,
P. Molnár
Positron Diagnostic Center
Background: In the treatment of liver metastates, the use of radio frequency abla-
tion (RFA), which is accompanied with lower risks, can serve as an alternative to
resection. This intervention may be performed in the case of foci that are of precise
and definite size and number. During the intervention electrodes are led to the
tumor focus, which is heated to a high temperature with the aid of electromagnetic
waves. The examination of the effectiveness of RFA is difficult due to the limitations
of CT and MR imaging in differentiating a viable tumor from reactive changes. PET/
CT offers a possibility to detect residual viable tumor before inflammatory process-
es develop.
Material and methods: We performed PET/CT exams before and after (within 24
hours) RFA. In addition to the routine PET/CT exams, 3-phase liver exams were
performed with the injection of Omnipaq IV contrast agent. The patients required
special treatment including the prescribed 24 hours of bed rest.
Results: In our presentation we would like to introduce the cases of two patients
who participated in examinations at our Institute before and after the intervention. In
both cases the presence of residual viable tumor tissue was confirmed.
Conclusions: Compared to other examination methods, the advantage of a follow-
-up performed with a PET/CT is that the presence of viable malignant tissue rem-
nant can be determined with great certainty, and therefore the succes of the abla-
tion can be settled in the first 24 hours following the intervention. It offers the possi-
bility of early reintervention.
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THE REQUIREMENT OF FURTHER IMAGING EXAMINATIONS TO
CLARIFY BONE SCAN ABNORMALITIES OF ONCOLOGICAL PATIENTS
IN THE AGE OF MDCT AND PACS
B. Kovács, T. Györke, K. Karlinger, V. Bérczi
Semmelweis University, Budapest, Hungary
Background: Due to the low specificity of bone scintigraphy, further imaging ex-
aminations are frequently required in order to clarify the etiology of positive bone
scan findings. MDCT is very useful in the evaluation of bone abnormalities based
on high and isotropic resolution. In the frame of oncological staging, cross-section-
al imaging modalities have become the standard imaging method of choice. The
PACS system allows a good access to these investigations.
Material and methods: Bone scintigraphy images were compared with chest, ab-
dominal and pelvic MDCT examinations of 78 oncological patients.
Results: In 31 cases the lesions were metastatic, while, based on CT appearance;
in 32 patients the lesions were benign. In 11 cases the morphology of the lesions
was equivocal. In 4 patients the CT has shown no corresponding abnormalities.
Conclusion: In the 80.5% revisiting, CT scans were sufficient to determine whether
a positive lesion on bone scintigraphy was benign or malignant. In the case of bone
scan abnormalities the comparison with previously performed MDCT images may
help to make a final diagnosis without further imaging examinations.
ABSENT CUMULATION OF META-IODO-BENZYL-GUANIDINE (MIBG)
IN HISTOLOGICALLY VERIFIED NEUROBLASTOMA IN CHILDHOOD
ON THE WHOLE BODY AND SPECT/CT SCAN
K. Zámbó1, G. Ottófy2, Zs. Szabó1, S. Szekeres1, M. Sarkadi1, E. Schmidt1
1Department of Nuclear Medicine, University of Pécs, Hungary, 2Pediatric Clinic,
University
of Pécs, Hungary
Background: The aim of the study was the examination of absent MIBG cumulation
in the primary tumor tissue in cases of verified neuroblastoma in childhood by SPECT/
/CT studies.
Material and methods: Two children were examined after the 123I-MIBG injection.
Anterior and posterior whole body scintigraphy and completed SPECT/CT studies
of the chest and abdomen were performed.
Results:
1st patient (2.5-year-old girl): solid tumor tissue of 90 ¥ 70 ¥ 50 mm in size was
shown by abdominal US examination in December 2008. Distant metastases were
found by other imaging techniques. A stage IV neuroblastoma was histologically
proved. There was no 123I-MIBG cumulation in the primary tumor tissue, but in-
creased activity was found in other localizations.
2nd patient (3.5-year-old girl): she was observed from August 2006 because of pri-
mary neuroblastoma and chemotherapy was given several times. A retroperitoneal-
ly localized 45 ¥ 25 mm tumor was detected by US and MRI in December 2008.
Surgical state: the tumor connected strongly to the aorta, therefore only a biopsy
was performed. Histology: Schwann cell stromal component is ca. 25–30%. Most
of the tumor cells were  partially or completely differentiated ganglion cell popula-
tions. There was not any mitotic activity. The MIBG scan did not show any activity in
the retroperitoneal tumor  but increased activity was found in the liver with no  evi-
dence of liver metastasis.
Conclusion: The voluminous tumor mass, stage IV, well-differentiated tumor cells
and the previous chemotherapy could result in false negative 123I-MIBG findings, so
the results should be evaluated in the possession of the anamnestic data and the
results of other examinations.
ASSESSMENT OF THE EFFECTIVENESS OF RADIOFREQUENCY
ABLATION PERFORMED IN THE CASE OF LIVER METASTASES
BY USING AN FDG PET-CT EXAMINATION THROUGH PRESENTING
THE EXAMPLE OF ONE PATIENT
K. Kajáry1, Zs. Lengyel1, P. Molnár1, Sz. Szakáll1, Z. Bánsághi2
1Pozitron Diagnostics Center, Budapest, Hungary, 2Péterfy Sándor u. Hospital, Clinic
and Accident Center, Budapest, Hungary
Background: FDG PET-CT scans are a routinely recommended procedure for de-
tecting liver metastases in patients suffering from colorectal carcinomas. One method
in the treatment of the detected metastases is radiofrequency ablation but its re-
sults are hard to verify immediately. Hyperaemia exists around the zone of the inter-
vention for 2–3 weeks, in accordance with which it is possible to detect false posi-
tives during a PET-CT examination performed between 1 day — 4 weeks after the
treatment. On the basis of the literature, PET-CT examinations performed within 24
hours after the RFA seem to be suitable for assessing its effectiveness, thereby
indicating the existence of residual viable tumors before the development of an
inflammatory reaction.
Material and methods: We performed PET-CT examinations four times on our pa-
tient  suffering from a rectal tumor. The third examination was within 24 hours after
the RFA of a solitary hepatic metastasis.
Results: At first/initially we suspected a lung metastasis, which was removed. Dur-
ing a follow-up examination in 7 months, we found a solitary accumulation in the
liver indicating a metastasis, upon which an RFA was later performed. During the
examination made within 24 hours of the intervention we detected an accumulation
indicating viable residuum on the edge of the ablated area. The PET-CT examina-
tion performed 3 months after that found the progression of the accumulation in
question.
Conclusions: The FDG PET-CT examination, in addition to showing the hepatic
metastasis sooner than the other imaging examinations, also provided additional
information about whether the RFA was complete or not.
ONCOLOGICAL CASES WITH PET/CT
Sz. Szakáll, K. Kajáry, P. Molnár, Gy. Tóth, Zs. Lengyel
Positron Diagnostics Center, Budapest, Hungary
Several factors should be considered in the analysis of a PET/CT study.  Factors
such as the circumstances of examination, physical parameters of the scans, distri-
bution of the injected tracer, biological behavior of the basic and associated dis-
eases or the changes induced by previous therapies may influence the final con-
clusions of the study.
Through case reviews, the authors demonstrate the advantages and limitations of
PET/CT imaging.
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THE ROLE OF ATYPICAL SENTINEL LYMPH NODES
M. Papós1, 2, G. Mohos3, M. Lázár1, 2, J. Varga3, E. Kis3, K. Kapitány3, T. Séra1, 2,
J. Oláh3, I. Korom3, L. Kemény3, L. Pávics1
1Department of Nuclear Medicine, University of Szeged, Hungary, 2Euromedic
Diagnostics Ltd., Szeged, Hungary, 3Department of Dermatology and Allergology,
University of Szeged, Hungary
Background: In patients with malignant melanoma (MM) of the trunk and the ex-
tremities the usual locations of sentinel lymph nodes (SN) are the cervical, axillary
and inguinal regions. Some authors found SN of atypical localization in 3–10% of
the cases.
The aim of this study was to analyze the frequency of atypical SNs and investigate
the malignant involvement of these SNs.
Material and methods: Preopeative SN mapping was performed in 665 consecu-
tive MM patients applying 99mTc-nanocolloids (Senti-Scint) using the gamma cam-
era technique. Intraoperative SN location was performed using the gamma probe
method.
Results: An atypical SN was found preoperatively in 54 cases (8%): only atypical
SN was detected in 11 cases, both typical and atypical SNs were revealed in 43
patients. In 37 cases the biopsy of the atypical SN was performed. Atypical SNs
showed MM involvement in 10 cases (27%): in 3 patients only atypical SN was
detected, in 6 cases the typical and atypical SNs were also involved, although met-
astatic MM cells were detected only in the atypical SN with negative typical SN in
one patient. More than two-year clinical follow-up was possible in 24 patients: 3
patients died in association with MM (all of them showed MM involvement of both
typical and atypical SNs).
Conclusions: We detected atypical SNs  atthe same frequency  as  it was previous-
ly described. On the basis of the common MM involvement of atypical SNs, we
suggest the biopsy of these SN-s.
INTERESTING CASES OF FDG PET-CT EXAMINATION
K. Kajáry, Zs. Lengyel, P. Molnár, Sz. Szakáll
Positron Diagnostics Co., Budapest, Hungary
Background: Today, for numerous tumors, PET or particularly PET-CT examina-
tions performed with FDG are procedures routinely utilized in staging and re-stag-
ing. They are also used to indicate the location for biopsies, non-invasively estimate
the degree of malignancy, confirm or refute recurrence, indicate the target mass for
radiation therapy and assess the effectiveness of therapy. In everyday work, we also
find quite a few interesting cases of FDG distribution patterns that deviate from the
ordinary. In the case of these patients if we do not have sufficient foresight we could
even make incorrect conclusions with our opinions.
Materials, methods and results: In our present poster we have disclosed the im-
ages of some patients in whom we found a distribution of radiopharmaceuticals
during the course of an FDG PET-CT examination that deviated from the ordinary,
and that was instructive.
Conclusions: The primary significance of FDG PET-CT examinations with an atyp-
ical appearance is that they indicate the doctor the importance of making the diag-
nosis. In addition to inspecting the images thoroughly, the doctor should always be
fully aware of the patient's exact/detailed case history and the reasons for accumu-
lations causing false positives or false negatives.
INOPERABLE PARAGANGLIOMA: A CASE REPORT
V. Tóth1, I. Balogh2, Z. Tóth1
1PET-CT Ltd., Budapest, Hungary, 2Department of Nuclear Medicine, Uzsoki Hospital,
Budapest, Hungary
Background: Paraganglioma is a rare neuroendocrine tumor; therefore it is usually
difficult to specify its characteristics. Nuclear medicine methods have great impor-
tance in the diagnosis of paraganglioma. Our case was a retroperitoneal inopera-
ble paraganglioma identified by CT, but  the US guided biopsy was unable to give
exact histological characterization.
Material and methods: I-123 MIBG, In-111 Octreoscan, low dose CT and F-18 FDG
PET-CT examinations were performed. I-123 MIBG scan was made 24 and 48 hours,
while In-111 Octreoscan images were made 24, 48 and 72 hours after the tracer
injection. Every examination included whole body, additional planar and SPECT
images. For the SPECT and CT fusion images MEDISO-Interview XP Software was
used. Whole body PET-CT exam included plain CT and 2D emission PET.
Results: All nuclear medicine methods detected tracer accumulation in the retro-
peritoneal tumor but unlike the I-123 MIBG scan, both with the Octreoscan and PET
method aspecific sites of tracer uptake were also found. CT could help to localize
the origin of these aspecific lesions. The I-123 MIBG accumulation was also the
highest - determining the therapy of choice i.e. I-131 MIBG.
Conclusions: Nuclear medicine plays an important role in the diagnostics of
paraganglioma. These methods give the only possibility to determine the proper
therapy. However, the verification of the origin of aspecific signs is also of great
importance. For this purpose, we have to use other imaging modalities, in our case:
CT. It is crucial to find the specific, non surgical therapy.
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INTRAOPERATIVE IMPRINT CYTOLOGY IN SENTINEL LYMPH NODES
OBTAINED BY RADIOGUIDED SENTINEL NODE BIOPSY IN BREAST
CANCER PATIENTS
M. Lázár1, S. Hamar2, L. Kaizer2, Gy. Lázár3, Zs. Simonka3, K. Ormándi1,
A. Paszt3, T. Séra5, A. Palkó4, T. Mikó2, L. Pávics5
1Euromedic Diagnostics Ltd., Szeged, Hungary, 2Department of Pathology, University
of Szeged, Hungary, 3Department of Surgery, University of Szeged, Hungary,
4Department of Radiology, University of Szeged, Hungary, 5Department of Nuclear
Medicine, University of Szeged, Hungary
Background: Axillary lymph node clearance can be avoided in the majority of breast
cancer patient by using radioguided sentinel node biopsy, though in approximate-
ly one fifth of the patients the intervention has to be performed in a second opera-
tion. The number of these operations can be decreased by intraoperative imprint
cytology therefore we decided to introduce this method. The aim of this study was
to evaluate the feasibility and efficacy of imprint cytology.
Material and methods: Eighty-five patients with breast tumour (one bilateral) were
enrolled in the study. The technique of radioguided sentinel node biopsy was not
changed (intra- or peritumoral administration of 150 MBq 99mTc-Senti-Scint, senti-
nel node mapping, intraoperative gamma probe detection), and we continued to
combine it with the blue dye technique. But sentinel node removal was performed
first, and the samples were directly carried to the Department of Pathology for im-
print cytology, and tumour removal was carried out after all this. We were informed
about the result by phone. In case a positive result was reported, we performed
axillary block dissection as well.
Results: Imprint cytology was positive in 13 cases, which were all proved by later
full examination, but the final results showed metastatic involvement in an addition-
al 7 cases.
Conclusions: If well organized, the method is well applicable, although it slightly
extends the time of surgery. In spite of providing false negative result in 8% of cas-
es, imprint cytology made it possible to avoid second operation in 15% of all pa-
tients, and no unnecessary intervention was made due to false positive results.
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OCTREOSCAN SCINTIGRAPHY AND FDG PET-CT INVESTIGATION
OF A PRIMARY SMALL BOWEL NEUROENDOCRINE CANCER
WITH HEPATIC METASTASIS
T. Györke1, 3, V. Tóth3, Zs. Szabó4, M. Rajtár5, K Máhr6, Gy. Nagy7, A. Oláh8,
P. Gyürüs9, N. Kránitz9, K. Borka2, A. Fekésházy3
1Department of Diagnostic Radiology and Oncotherapy, Semmelweis University,
Budapest, Hungary, 2II Department of Pathology, Semmelweis University, Budapest,
Hungary, 3PET-CT Medical Diagnostics Ltd., Budapest, Hungary, 4Department
of Nuclear Medicine, University of Pécs, Hungary, 5Department of Nuclear Medicine,
Bács-Kiskun County Hospital, Kecskemét, Hungary,  Zala County Hospital,  Hungary,
6Department of Oncology, Zalaegerszeg Petz Aladár County Teaching Hospital, Gyõr,
Hungary, 7Department of Radiology, Zalaegerszeg Petz Aladár County Teaching
Hospital, Gyõr,  Hungary, 8Department of General Surgery, Zalaegerszeg Petz Aladár
County Teaching Hospital, Gyõr, Hungary, 9Pathology Center, Zalaegerszeg Petz Aladár
County Teaching Hospital, Gyõr, Hungary
Background: In the diagnosis of neuroendocrine tumors (NET) several imaging
methods can be applied. Somatostatin receptor scintigraphy has a high impact
among nuclear medicine (NM) modalities and FDG PET may also depict these
diseases. The complementary result of the two methods in a case of primary small
bowel NET with hepatic metastasis will be presented.
Material and methods: Case report: A 51-year-old male patient was investigated
because of skin itch. Abdominal ultrasonography detected a focal liver lesion (LL).
The histology based on US guided core biopsy was NET. Beside CT and MR inves-
tigations Octreoscan SPECT-CT (O-SPECT-CT) and FDG PET-CT investigations
were performed.
Results: The morphologic imaging modalities detected only the LL. There was high
level accumulation in the LL at O-SPECT-CT and no such high grade uptake distin-
guishable from physiological bowel activity was detected elsewhere. PET-CT showed
mildly increased FDG uptake in the LL and an intense focal activity in the ileum.
According to this uptake CT images of PET-CT showed a small suspicious soft
tissue mass of the bowel. Histological investigation following the resection of the
liver and the bowel provided the diagnosis of a primary small bowel neuroendo-
crine cancer with hepatic metastasis.
Conclusions: Functional imaging modalities performed in this case showed the
different biologic behaviour of the primary tumor and its metastasis. This case sup-
ports the requirement for a combined use of several imaging modalities even with
the combination of multiple NM methods according to the difficulties in the diag-
nostic work up of NET.
POTENTIAL ROLE OF 18F-FDG PET-CT IN THE STAGING OF HEAD
AND NECK CANCER — PRELIMINARY RESULTS
V. Tóth1, Z. Tóth1, A. Fekésházy1, T. Klinkó2, D. Sinkó2, Cs. Weisz2, Á. Mayer2
1PET-CT Medical, Diagnostic Ltd., Budapest, Hungary, 2Uzsoki Hospital, Oncoradiology
Centre, Budapest, Hungary
Background: We assessed the potential role of PET-CT in the complex treatment
planning of head and neck cancer (HNC).
Material and methods: In the present study 10 whole body PET-CT examinations
were performed after radiotherapy presimulation and mask production for patients
with squamous cell head and neck cancer (SCHNC). Seven of the ten patients had
mesopharyngeal, one patient had epipharyngeal, and another one had laryngeal
cancer. In one case the indication for the examination was cervical lymph node
metastasis with unknown primary tumor. The PET-CT examinations were obtained
on a compatible examination table with the use of positioning aids (mask), and in
the same position as in radiotherapy. The subsequent 3D planned radiotherapy
contained PETCT based target volume delineation information.
Results: In 6 of the 10 cases the PET-CT led to modification in the patient's further
treatment. In 4 cases lymph node metastases were identified although in the previ-
ous stage there were none detected, which resulted in additional chemotherapeu-
tic treatment. In 2 cases the previously planned target volume was altered accord-
ing to the information provided by PET-CT.
Conclusions: PET-CT may help in the evaluation of regional lymph node involve-
ment in SCHNC, thus providing important information for complex therapeutic man-
agement planning. Further comprehensive studies are needed to assess the exact
role of PET-CT and to evaluate the accuracy of PET-CT based therapy planning.
CRITICAL POINTS IN AN INTERLABORATORY COMPARISON
T. Séra1, 6, J.C. Dickson2, L. Tossici-Bolt3, A. Varrone4, K. Tatsch5, L. Pávics1
1Department of Nuclear Medicine, University of Szeged, Hungary, 2Institute of Nuclear
Medicine, University College Hospital, London, United Kingdom, 3Department of Medical
Physics and Bioengineering, Southampton University Hospital NHS Trust, Southampton,
United Kingdom, 4Department of Clinical Neuroscience, Psychiatry Section, Karolinska
Institute and Stockholm Brain Institute, Stockholm, Sweden, 5On behalf of all
participating centres, European Network of Excellence for Brain Imaging (a Project
of EANM Research Ltd, Austria), 6Euromedic Diagnostics Szeged Kft., Szeged, Hungary
Background: The Neuroimaging Committee of the EANM recently initiated the gen-
eration of a database of [123I]FP-CIT (DaTSCAN) SPECT scans of healthy controls
through collaboration between 15 European institutions. In order to check on and
maintain the quality of SPECT imaging in the participating laboratories, the equip-
ment was validated through an interlaboratory comparison study.
Material and methods: Visits were made by a physicist to the 15 participating
institutions to perform the protocol on the 24 SPECT cameras in conjunction with
the locally assigned project leader. Via the application of 99m-Tc, 57-Co and 123-I
radioisotopes, point and flood sources, fillable SPECT and tissue-equivalent brain
SPECT phantoms, the intrinsic and extrinsic uniformities, COR, and spatial resolu-
tion were determined. SPECT studies of the brain phantom were performed with
different striata/backround ratios.
Results: Several problems emerged during the study. In some cases, the radioac-
tive solution started to leak from the brain shell. Delivery of the phantoms, or the
123-I solution was sometimes delayed. In some centres, the acquisition software
did not permit the setting-up of the parameters required by the protocol, and ser-
vice assistance was necessary. Other problems occurred too. The data obtained
have been submitted to the core lab and are currently under evaluation.
Conclusion: Prevention of the above-mentioned problems would significantly in-
crease the success and lower the costs of such studies.
VARIOUS APPEARANCE OF OSSEOUS METASTASES ON PET/CT
N. Fedinecz, Zs. Hascsi, I. Garai
PET-CT Medical Diagnostic Ltd., Debrecen, Hungary
The accurate localization and assessment of the extent of metastatic bone disease
is essential for the selection of an optimal therapy in oncological patients. To detect
bone metastases, fluorodeoxyglucose (FDG) positron emission tomography (PET)
offers metabolic information including the assessment of tumor viability and activi-
ty. Fused images produced by PET/CT, through computed tomography (CT) pro-
vide additional morphologic information and precise localization of bone involve-
ment. For a correct evaluation of PET/CT examination you have to know the different
appearances of metastatic bone lesions. We would like to demonstrate different
images of osseous metastases.
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SEVEN YEARS’ RESULTS WITH 166HOLMIUM-PHYTATE TREATMENT
OF CHRONIC SYNOVITIS. PHASE I-IIA, RANDOMIZED, INCREASING
DOSAGE, SINGLE-BLIND, PLACEBO-CONTROLLED COMPARATIVE
STUDY
M. Szentesi, Z. Nagy, P. Géher
Chair of Rheumatology and Physiotherapy, Department of Rheumatology, Semmelweis
University, Budapest, Hungary
Background: The aim of the study was the examination of the anti-inflammatory
effect of 166-Holmium-phytate injection.
Material and methods: 31 patients suffering from chronic synovitis, rheumatoid
arthritis and seronegative spondylarthritis were examined.
The patients were randomly distributed into four treatment groups:
— group I — holmium phytate injectable suspension marked by 185 MBq 166Ho +
40 mg of 1 ml triamcinolone acetonide + 1 ml of 1% lidocaine injection (injections);
— group II — 555 MBq 166Ho + injections;
— group III — 925 MBq 166Ho + injections;
— group IV — solely 40 mg of 1 ml triamcinolone acetonide + 1 ml of 1% Lid.
injection.
Inflammatory activity tests were done based on the following parameters:
1. Measurement of the swelling of the knee-joint [cm]; 2. Flexion — heal buttocks
distance [cm]; 3. Degree of knee-joint pain; 4. Visual Analogue Scale (VAS 1-100);
5. Patient's opinion on inflammation of knee-joint (VAS 1–100); 6. Doctor's opinion
on given inflammation of knee-joint (VAS 1–100).
Results: Even after a 7-year-period, 88.2% of the findings were rated as excellent or
good. 86.66% of the patients do not need another punction even after a 7-year-
period. During the study period, the inflammation decreased in the group receiving
555 and 925 MBq.
Conclusion: The Ho-166 isotope is an effective radiopharmacon in treating synovi-
tis. Due to its physical parameters it is optimal to treat large joints (knee) and medi-
um size joints (hips, shoulder, elbow, wrist, ankle). The effective dose is 555–925
MBq.
166HOLMIUM-PHYTATE-RADIOSYNOVIORTHESIS IN RHEUMATOID
ARTHRITIS. FIVE YEARS’ CLINICAL RESULTS, PHASE III PROSPECTIVE
STUDY
M. Szentesi, Z. Nagy,  P. Géher
Chair of Rheumatology and Physiotherapy, Department of Rheumatology, Semmelweis
University, Hungary, Polyclinic of the Hospitaller Brothers of St. John of God, Budapest,
Hungary
Background: The aim of the study was the examination of the anti-inflammatory
effect of 166-Holmium-phytate injection.
Material and methods: Phase III, prospective study. We examined 30 patients suf-
fering from chronic synovitis, and rheumatoid arthritis were examined. The protocol
was commenced with screening. The patients were selected according to inclu-
sion and exclusion criteria.
Holmium phytate injectable suspension marked by 600 MBq 166Holmium phytate
injectable suspension, and 40 mg of 1 ml triamcinolone acetonide and 1 ml of
lidocaine 1%. There was a 60-month follow-up period after the administration of the
isotope.
The inflammatory activity of the affected knee-joint was tested prior to treatment,
and 3, 6, 9, 12, 24, 36, 48 and 60 months after treatment. The evaulation was based
on the criteria as described by Müller, Rau and Scütte, while the score system was
developed by the authors.
Results: During the study period, the inflammations decreased. In the first five years
excellent and good results were recorded in 93.3%. Five years after radiosynovior-
thesis 93.3% of patients did not need another punction. We found no deviations in
either haematological or chemical parameters during the study period.
Conclusion: The Holmium-166 phytate isotope is an effective radiopharmacon  in
treating synovitis. Due to its physical parameters it is optimal to treat large joints
(knee) and medium sized joints (hips, shoulder, elbow, wrist, ankle). The effective
dose is 555–925 MBq.
ULTRASOUND MONITORING OF SYNOVIAL THICKNESS AFTER
166-HOLMIUM-PHYTATE RADIOSYNOVIORTHESIS.
FIVE-YEAR RESULTS, PHASE III PROSPECTIVE STUDY
M. Szentesi1, Zs. Farbaky1, P. Géher1
1Chair of Rheumatology and Physiotherapy, Department of Rheumatology, Semmelweis
University, Hungary, Polyclinic of the Hospitaller Brothers of St. John of God, Budapest,
Hungary, 2Institute of Isotopes Co. Ltd., Budapest, Hungary
Background: The aim of the study was to measure the synovial thickness after 166-
Holmium radiosynoviorthesis by sonography.
Material and methods: Phases III, prospective study. 30 patients suffering from
chronic synovitis, rheumatoid arthritis were examined. The protocol commenced
with screening. The patients were selected according to inclusion and exclusion
criteria.
Holmium phytate injectable suspension marked by 600 MBq 166Holmium phytate
injectable suspension, and 40 mg of 1 ml triamcinolone acetonide and 1 ml of
lidocaine 1%. There were 60 months follow-up period after the administration of the
isotope. Inflammatory activity of the affected knee-joint was tested prior to treat-
ment, and the 3th and 3, 6 12, 24, 36, 48 and 60 months after treatment. We mea-
sured the synovial thickness the following locations: In the midline, lateral and me-
dial, by the condylus of femur medial and lateral.
Results: During the study period, inflammation decreased. In the first five years
excellent and good results were recorded in 93.3%. Five years after radiosynovior-
thesis 93.3% of patients did not need another punction. The thickness of the syn-
ovia decreased significantly. We find a significant correlation between the synovial
thickness and the clinical improvenes.
Conclusion: The 166-Holmium-phytate is an effective new radiopharmacon in the
treatment of synovitis. We detect the clinical improvement by sonography. The ef-
fective dose is 600 MBq.
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ULTRASOUND MONITORING OF SYNOVIAL THICKNESS AFTER
166-HOLMIUM-PHYTATE RADIOSYNOVIORTHESIS — SEVEN YEARS’
RESULTS (PHASE I–IIA, COMPARATIVE, RANDOMIZED, SINGLE-BLIND,
PLACEBO-CONTROLLED STUDY WITH INCREASING DOSAGE)
M. Szentesi, P Géher, Zs. Farbaky
Chair of Rheumatology and Physiotherapy, Semmelweis University, Budapest, Hungary
Background: The aim of the study was to measure the synovial thickness after
166-Holmium radiosynoviorthesis by sonography.
Material and methods: 31 patients suffering from chronic synovitis, rheumatoid
arthritis, or seronegative spondylarthritis were examined. The patients were ran-
domly distributed into four treatment groups:
— group I — 185 MBq 166Holmium phytate (166-Ho) injectable suspension and 40
mg of 1 ml triamcinolone acetonide and 1 ml of lidocaine injection 1%, (injections);
— group II — 555 MBq 166-Ho, and injections;
— group III — 925 MBq 166-Ho and injections;
— group IV — solely 40 mg of 1 ml triamcinilon acetonide and 1 ml of lidocaine
injection 1%.
There was an 84-month follow-up period after the administration of the isotope. We
measured synovial thickness at the following locations: In the midline, laterally and
medially, medial and lateral to the condylus of the femur.
Results: The thickness of the synovia decreased significantly in groups II (555 MBq)
and III (925 MBq). After transient improvement (the steroid effect) the thickness of
the synovia began to increase in the group I (185 MBq) and in the control group.
We have found significant correlation between  synovial thickness and the clinical
improvement.
Conclusions: The 166-Ho is an effective new radiopharmacon in the treatment of
synovitis. We detect clinical improvement by sonography. The effective dose is
555–925 MBq.
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NOVEL IMAGE EVALUATION SYSTEM FOR MULTI-MODALITY IMAGING
B. Kári1, Cs. Pintér2, N. Zsótér2, L. Papp3, Cs. Beján2, G. Németh2, Z. Barta4
1Department of Diagnostic Radiology and Oncotherapy, Faculty of Medicine,
Semmelweis University, Hungary, 2Mediso Ltd., Budapest, Hungary, 3Nuclear Medical
Clinic, Schleswig-Holstein University Campus, Kiel, Germany, 4PET-CT Medical
Diagnostic Ltd., Budapest, Hungary
Background: Most of the uncertainty in non-invasive imaging diagnostics is reduc-
ible with high efficiency by applying multi-modality imaging technology. Three
modality integrated imaging systems — SPECT/PET/CT — have been constructed
in order to create the “high-tech” conditions in a cost-effective way, mainly for func-
tional diagnostics. Nevertheless, novel image processing technology had to be
developed to perform the 3D presentation by simultaneous and fused way to en-
hance the advantages of each modality.
Material and methods: The image evaluation system — InterView® Fusion — can
be activated individually and from the upgraded InterViewXP® system. Its basis is
our self-developed DICOM database supported by Windows Vista 32/64bit or XP.
Graphics is powered by high performance GPU (nVIDIA ) algorithms with 2 ∏ 4
Mpixel resolutions. Presentations of the multi-modality images are provided by pre-
defined and user defined layout sets. Several versatile ROI, VOI techniques are
available for quantitative and semi-quantitative analysis. The image processing sys-
tem supports both auto and manual co-registration methods in order to present the
fused image of various modalities. Aunique transparent colorization procedure has
been developed for simultaneous presentation of max. four modality fusion tech-
niques. The particular image processing operations can be accessed by pop-up
menus, hotkeys combinations and/or user-localized toolboxes. Reporting of the
results may be obtained through a user pre-defined template set on either hard-
copy or optical media.
Results: Stability test and validation of InterView® Fusion is running in many as-
signed clinics now.
Conclusion: The novel image evaluation system will be suitable to apply as a mo-
dality manufacturer independent image processing system too.
DETERMINING PERFORMANCE PARAMETERS OF THE SMALL ANIMAL
PET SCANNER MINIPET-II ACCORDING TO NEMA NU-4 STANDARD
S.A. Kis1, M. Emri1, I. Lajtos1, L. Trón1, J. Imrek2, I. Valastyán2, G. Kalinka2,
D. Novák2, J. Molnár2, Gy. Hegyesi2, L. Balkay1
1Institute of Nuclear Medicine, University of Debrecen, Hungary, 2Institute of Nuclear
Research, Hungarian Academy of Sciences, Debrecen, Hungary
Background: In vivo imaging of small laboratory animals is a valuable tool in the
development of new drugs. For this purpose a small animal PET scanner (MINIPET-
II) has been developed in our institute, as part of an R & D project.
After the first successful technical and biological studies, our goal was to determine
the performance parameters of the scanner according to NEMA NU-4 standard.
Results: The numerical values of spatial resolution as measured at 1 mm, 10 mm
and 20 mm from the centre of FOV were 1.12 mm, 1.23 mm and 1.45 mm, respec-
tively. The absolute sensitivity of the scanner is 2.13% applying 5ns coincidence
time window. The time resolution of detector pairs was 2.9 ns and the maximal
detectable count rate is 650.000 cps. Appropriate total radioactivity depends on the
spatial distribution of the tracer. Accordingly, using point source or mouse and rat
phantom filled up with FDG the total activity should not exceed approximately 40
MBq, 80 MBq and 150 MBq, respectively. Following the successful performance
tests the first measurements of radiotracer distributions in small laboratory animals
have already been completed.
Conclusion: Based on these results MiniPET-II can competewith any other PET
scanner with a similar detector system in every aspect.
THE SOFTWARE SYSTEM OF THE MINIPET-II SCANNER
M. Emri1, G. Opposits1, S.A. Kis1, L. Trón1, J Imrek2, D. Novák2, J. Molnár2,
Gy. Hegyesi2, L. Balkay1
1Institute of Nuclear Medicine, University of Debrecen, Hungary, 2Institute of Nuclear
Research of the Hungarian Academy of Sciences, Debrecen, Hungary
Background: The examination of small animals using high resolution in-vivo imag-
ing techniques is a crucial tool in pharmaceutical research projects. To suffice this
demand, a small animal PET camera has been developedin our institute as part of
a R + D project.
The aim of the study was to develop a complete software system supporting 3D
PET-data acquisition and the appropriate image reconstruction and image pro-
cessing.
Results: Using cluster-technique we have implemented a network based data ac-
quisition system. This system comprised programs running on the embedded Linux
environment of the detectors and the data acquisition computer. A signal process-
ing software system running on an eight-cored computer controls primary data
processing. To support the image reconstruction, we developed a software system
capable of running either on multi-core computers, or clusters, and computers us-
ing graphical processing units as mathematical co-processors. In addition to the
conventional methods, the newest OpenGL and OpenCL tools were also used in
the processing and visualization of the reconstructed images.
Conclusion: Based on the successful performance test measurements and the first
biological studies the software system of the MiniPET-II is an appropriate package
to support in vivo imaging.
COMPLEX SOFTWARE FRAMEWORK FOR TRACER KINETIC ANALYSIS
OF RECEPTOR LIGAND BINDING
G. Opposits, AS. Kis, P. Mikecz, L. Balkay, L. Trón, M. Emri
Institute of Nuclear Medicine, University of Debrecen, Hungary
Background: Human and small animal PET receptor studies belong to the most
important in vivo tools of pharmaceutical research. Tracer kinetic analysis and dig-
ital brain atlas methods belong to the commonly used techniques to process imag-
es obtained by dynamic scanning. Regional analysis can be done either on the
basis of individually drawn brain regions or using regional databases of human-,
mouse- and rat brain atlases.
The aim of the study was to work out validated, complex software framework sup-
porting the effective processing of multi-subject binding experiments and model-
calculations.
Results: The Image Sorter is the first element of the software framework which con-
verts the format of the images arriving at the DICOM server of the institute to MINC
(a useful working format) and carries out each task in an executable automated
manner. Generation of summation images, MRI-PET registration and spatial stan-
dardization belong to the latter type of tasks. BrainTrace, a multimodal, interactive
image processing software have been developed for the interactive work up of im-
ages produced by the Image Sorter. The verification and the eventually necessary
correction of MRI-PET registration can be done by BrainTrace. The same program
can support the manual or brain atlas based drawing of regions required by the
tracer kinetic analysis as well as the evaluation of the parametric images. Brain-
Trace’s components responsible for model calculations were validated by PVELab
a Matlab based tracer kinetic software.
Conclusion: The developed software framework containing automated and inter-
active elements allows the routine work up of dynamical binding examinations car-
ried out using PET ligands.
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DEVELOPMENT OF A MONTE CARLO BASED ALGORITHM
FOR PET RECONSTRUCTION
A. Wirth1, Á. Cserkaszky2, Sz. Czifrus2, S. Fehér2, D. Légrády2, B. Kári1
1Department of Diagnostic Radiology and Oncotherapy, Semmelweis University,
Budapest, Hungary, 2Institute of Nuclear Techniques, Budapest University of Technology
and Economics, Hungary
Background: The presentation summarizes the results achieved so far within the
framework of the TeraTomo project. The aim of the project r is to develop a high-
speed PET algorithm optimized for graphics processors (GPU) which would pro-
vide more accurate reconstructions utilizing CT data.
Material and methods: The proposed Monte Carlo simulation technique makes it
possible to trace the trajectory of the photons produced in the positron annihilation
process through the scattering events inside the body. By linking the Monte Carlo
calculation to the usual filtered backprojection, we can elaborate a tecgnique   which
is more precise than the conventional iteration algorithm. The drawback of the Mon-
te Carlo method is the need of massive computing capacity. However, in the mean-
time, it is an ideal subject to GPU based calculations which might be faster than
CPU based ones by two orders of magnitude.
Results: The Monte Carlo photon transport calculation involves a lot of different
methods which could be of primary importance regarding the accuracy and speed
of the final algorithm. The methods taken into account are the Woodcock algorithm,
different techniques of variance reduction based on particle weight, together with
the possible approximations in the modeling of Compton scattering.
Conclusions: Our aim in the current phase of the TeraTomo project was to produce
a complete computational model which is capable of analyzing the aforementioned
parameters both on conventional and on graphics processors.
QUANTITATIVE EVALUATION OF TISSUE HETEROGENEITY IN PET
J. Vincze, Gabriella Vincze-Tiszay
HHEIF, Budapest, Hungary
Background: The aim of the study was the influence of tissue heterogeneity on
results of fitting nonlinear model equations to regional tracer uptake curves: with an
application to compartmental models used in positron emission tomography.
Material and methods: The limited resolution of PET devices implies that, in gener-
al, more than one tissue component, each with a different physiological status,
contribute to the measured signal in a volume element. In general, it is impossible
to recover the signals form the different components.
One possibility for examining the effects of tissue heterogeneity, the analytical meth-
od, is based on Taylor expansion of the expression for the tracer radioactivity around
the mean values of the parameters, and can be used for models which give the
tissue radioactivity as an explicit function of the models' parameters. The experi-
mental procedure we use follows tracer (FDG, 1-gluc, methyl-glucose, FESP) and
different kinetic models and algorithms. The steady state method was found to be
more sensitive to tissue heterogeneity than the dynamic method.
Conclusions: In conclusion, tissue heterogeneity may have profound effects. Some
parameters, which enter linearly in the model expressions for tissue radioactivity,
are, under normal conditions, comparatively insensitive to heterogeneity, and other
factors, such as noise and errors in the input function, can have more serious ef-
fects.
CT DOSE-OPTIMIZATION IN PET/CT EXAMINATIONS
L. Balkay1, N. Fedinecz2, H. Galgóczy2, Zs. Hascsi2, I. Garai2, L. Galuska1
1Institute of Nuclear Medicine, University of Debrecen, Hungary, 2PET-CT Ltd., Debrecen,
Hungary
Background: Performing FDG PET/CT, the effective dose for a patient is usually in
the range of 10–25 mSv. The dose issued by a radiopharmacon is approximately 6-
12 mSv and the effective dose of a CT examination is between 5–20 mSv, depend-
ing on the settings (kV, mA, mAs, pitch). However,  the optimal setting required for
a CT image of acceptable quality depends, to a large extent, on the explicit  figure
(and not just the weight ) of the patient. In this study, our goal was to optimize the
settings of CT examinations  using  two PETCT cameras.
Material and methods: The examinations were carried out on GE Discovery-ST
and Philips Gemini-TF PET/CT cameras. During the optimization we changed the
kV, pitch and mA values and applied the dose-modulation programs provided by
the manufacturer. For dose calculation we used the CTDI and DLP values and the
data of the "ImPACT" software.
Results: We could develop CT protocols by which, depending on the shape of the
patient, the effective dose of the CT can be decreased by as much as 10–50% in the
case of a Philips camera (bigger-smaller patient) and by 25–70% in the case of a
GE Discovery. The current dose values of the CT are between 2–6 mSv in a Philips
PETCT (smaller-bigger patient) and 3–8 mSv in a GE PETCT camera.
Conclusions: In PET/CT examinations, the effective dose for patients can be signif-
icantly decreased if we use protocols optimized for the patient's figure.
P23
ANATOMICAL LOCALIZATION IN PET BRAIN RECEPTOR STUDIES
Z. Megyesi, T. Spisák, S. A. Kis, G. Opposits, L. Balkay, L. Trón, M. Emri
Institute of Nuclear Medicine, University of Debrecen, Hungary
Background: Human and small animal PET receptor studies belong to the most
important in vivo tools of pharmaceutical research. The analysis of dynamic PET
data requires the use/application of tracer-kinetic and digital brain atlas related
image processing methods. The investigation of receptor binding can be support-
ed by manually drawn regions or the application of human, mouse or rat brain atlas
databases. The latter plays an important role in the anatomical localization, as well.
None of the available database software products are capable of handling more
than a single data base.
The aim of the study was to work out a platform-independent framework and appli-
cation that, beyond elementary image processing tasks, enables us to handle sev-
eral brain atlas databases at the same time.
Result: In accordance with the main objectives a complete program called Brain-
Loc has been developed. It supports Talairach Daemon, LONI Probabilistic Brain
Atlas (LPBA) and International Consortium for Brain Mapping (ICBM) databases.
Based on the strength of this database selecting strategy, a brain atlas dependent
numerical value can be rendered to a given location describing the probability that
it belongs to a possible anatomical structure. The operation of the elaborated soft-
ware has been validated using BrainVoyager and Anatomy Toolbox.
Conclusion: BrainLoc may be instrumental in the post processing phase of recep-
tor studies by the miniPET-II small animal PET scanner.
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RADIOPHARMACEUTICALS
P27
MANUFACTURING [18F]-FALLYPRIDE
N. Pótári, I. Jószai, T. Nagy, T. Márián, L. Galuska, L. Trón, P. Mikecz
Department of Nuclear Medicine, Medical and Health Science Center, University of
Debrecen, Hungary
Background: Dysfunction in dopaminergic neurotransmission has been implicat-
ed in a number of neuropsychiatric disorders including Parkinson's disease, Alzhe-
imer's disease, schizophrenia, and Huntington's disease. The availability of small
molecule PET ligands that can selectively target dopamine receptors (D1–D4), trans-
port and synthesis is important to learn more about of these complex diseases.
Fallypride radiolabeled with fluorine-18 was first synthesized by Mukherjee in 1995,
and is currently being used as a dopamine D2/D3 receptor-imaging agent in PET
studies because of its selectivity, affinity, and reversibility. The first article about
[18F]-Fallypride was published in 1993. Since that time more than 100 publications
have been written. Our aim was to make this tracer available for biology and possi-
ble human studies in Hungary.
Material and methods: We used materials suitable for GMP, and of the highest
purity available for the synthesis of [18F]-Fallypride. The synthesis was a one-step
nucleophile substitution accomplished by isocratic HPLC purification, and followed
by solvent change on a SPE cartridge and formulation. The quality of the [18F]-
Fallypride was investigated with HPLC and TLC methods.
Results: The reaction yield was 20% without decay correction. The total synthesis
time was 1 hour including the 20-minutes reaction time. In a typical experiment from
30GBq 18F- we could produce 7 GBq [18F]-Fallypride. The synthesized [18F]-Fallyp-
ride had a physical concentration of 3–5 nmol/ml and its specific activity was about
70–200 GBq/mmol (1900–5400 mCi/mmol). The product was tested using small an-
imal model (mice). The animals were investigated using the autoradiography tech-
nique and a mini-PET scanner, which was developed in our institute. The authoriza-
tion of [18F]-Fallypride for purposes of investigation in humans is in progress.
IMPROVED PRODUCTION OF GAS PHASE [11C]CH3I
BY I2-CONCENTRATION-CONTROL
T. Cservenyak, A. Johayem, C. Schweinsberg, P.A. Schubiger, G. Westera
Center for Radiopharmaceutical Science of ETH, PSI and USZ, University Hospital,
Zurich, Switzerland
11C-methyl iodide is the most important starting material in the production of
11C-labelled tracers used for Positron Emission Tomography (PET). The method of
choice for its production is the high temperature iodination of 11C-methane in a
circulating gas phase (Larsen, Appl Radiat Isot 1997).
Since the yield is dependent on the I2 concentration in the gas phase (Link, Nucl
Med Biol 1997), we developed a spectroscopic method to determine the optimal
iodine concentration.
The heating temperature of the oven, which sublimates the iodine, is automatically
adjusted to achieve and keep this concentration during the reaction period.
The concentration of I2 in the gas phase was measured immediately behind the
iodine oven using a UV/VIS microspectometer equipped with a high-grade, low-
noise silicon detector suitable for the spectral range of 350–850 nm. The absor-
bance of I2 was measured in between 510–540 nm and continuously corrected for
background and the absorption of solid material on the walls of the quartz tube.
Finally the relationship between heating temperature and I2 absorbance was inves-
itgated.
The I2 concentration in the vapour phase was calculated by determination of the
amount of sublimated I2 in a continuous He2-gas flow. Preliminary experiments at a
flow rate of 50 mL/min for 1 h led to a concentration of 80 µMol/L for a stable absorp-
tion of 0.2 and a 11C-MeI yield of 30% (5 min after EOB, uncorrected). The optimal
concentration of I2 vapour is under investigation in ongoing experiments.
ELECTROMAGNETIC HYPERTHERMIA (ONCOTHERMIA®) SHOWS
ANTITUMORAL EFFECTS AS A SINGLE TREATMENT AND SEEMS
TO ENHANCE THE EFFECTIVITY OF COBALT IRRADIATION
— FIRST VETERINARY CLINICAL RESULTS
L. Balogh1 , G. Andocs2, J. Thuroczy1, A. Polyak1, T. Koncz1, O. Szasz3, A. Szasz3
1National "FJC" Research Institute for Radiobiology and Radiohygiene, Budapest,
Hungary, 2Veterinary Faculty, Szt. Istvan University, Budapest, Hungary, 3Faculty
of Engineering, Szt. Istvan University, Budapest, Hungary
Background: Advantageous thermal and induced non-thermal effects of electro-
magnetic hypertermia (EHT) in oncology is known for decades. This ever-develop-
ing technique has been utilized in human oncology for a long time but surprisingly
no veterinary clinical data are available therefore.
Material and methods: We applied EHT with capacitive coupled modulated
13.56MHz radiofrequency method (oncothermia OT). OT was provided as a single
treatment in 6 cases, and in a combination with fractionated Cobalt irradiation in 18
cases. Superficially located skin tumors (mastocytoma GrII, III 7 cases, 2 histiocyto-
mas), 5 malignant oral tumors (3 melanomas, 1 carcinoma), 3 osteosarcomas, 2
nasal cavity adenocarcinoma and 1 insulinoma were treated in dog patients and 2
feline mammary carcinoma and 3 soft tissue sarcoma cases were enrolled to the
study.
Results: Single OT resulted significant tumor size decrease 2 out of 6 cases, 3
stable disease and 1 progression of disease. Cobalt irradiation followed by OT
resulted 3/18 tumor-free status, 12/18 partial remissions, 2/18 stable disease, and
progression of disese in 1 case. Side effects eg.: erythema (2 cases), necroses (2
cases) occurred at the learning phase of technique, later on we could prevent this
side effects with the constant superficial and deep temperature control in or pa-
tients.
Conclusion: We concluded that local OT could be a useful tool as a single antitu-
moral modality but even more clinical utilities could be reached in a combination
with radiotherapy (maybe with chemotherapy as well) by the local increase of the
blood-perfusion. Further clinical studies needed to implement this novel technique
into veterinary oncological practice.
OTKA T042584 and T049708 EMIL-NoE 503569-2.2, IAEA CRP No E1.30.33
PRECLINICAL STUDIES
MANY RELEVANT DATA FROM A HOPELESS SINGLE VETERINARY
PATIENT — THE POOR LATE KAZMER
L. Balogh1, Zs. Kendik2, P. Csébi2, G. Andocs2, J. Thuroczy2, G. Németh3,
A. Polyak1, D. Mathe1,T. Koncz1, G. Janoki4, Gy.A. Janoki4
1National “FJC” Research Institute for Radiobiology and Radiohygiene, Budapest,
Hungary, 2Veterinary Faculty, Szt. Istvan University, Budapest, Hungary 3Mediso Ltd.,
Budapest, Hungary, 4Medi-Radiopharma Ltd., Radiopharmacy Ltd., Budapest, Hungary
Background: Kazmer, the 7-year-old castrated male cat presented at the Depart-
ment of Surgery, Veterinary Faculty (Budapest, Hungary) following a 2-month-his-
tory of fast progressing neurological signs. The cat underwent a thoroughphysical,
neurological and orthopaedic examination, complete blood testing, myelography
and CT examination. The initial diagnosis was tumor involvement of the 5th cervical
vertebra with no detectable metastases.
Material and methods: Cytoreductive surgery was performed within one week af-
ter the diagnosis. The histopathological examination of the removed mass revealed
low-differentiated fibrosarcoma of osseous origin. Two weeks after surgery the cat
was referred into our institute for further diagnosis and treatment. Multiple scinti-
graphic examinations were carried out by injecting 99mTc-MDP (Skeleton, Medi-
Radiopharma), 99mTc-DMSA(5) (Penta DMSA, Medi-Radiopharma), and 99mTc-MIBI
(Cardio-SPECT, Medi-Radiopharma).
Results: All the three radiopharmaceuticals showed significant focal uptake in the
neck region indicating the presence of remnant tumor tissue but nowhere else in
the body. In vivo 99mTc-MIBI wash-out examination and in vitro immunohistochemis-
try and real time PCR tests from the removed tumor proved the multidrug resistance
of the case. Post-surgical local irradiation (Cobalt-60, 12 ¥ 3 Gray) was given on a
Mo-We-Fri schedule. There was no improvement in the neurological signs, and the
cat started to lose  weight so euthanasia was  performed  at the owner's request.
Gross pathology, ex vivo nanoSPECT/CT examination of the excised neck region
and further histopathological examinations were carried-out.
Conclusions: Although the case we have presented proved to be totally un-treat-
able, it provided a lot of experience for the veterinary staff/team.
OTKA T042584 and T049708 EMIL-NoE 503569-2.2
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IMAGING OF REGIONAL RED BLOOD CELL MASS IN THE RAT BRAIN
BY HIGH-RESOLUTION, QUANTITATIVE NANOSPECT/CT TECHNOLOGY
D. Máthé1, I. Portörõ2, G. Németh1, A. Eke2, Gy.A. Jánoki3
1Mediso Ltd., Budapest, Hungary, 2Institute of Human Physiology and Clinical
Experimental Research, Semmelweis University, Budapest, Hungary,
3Medi-Radiopharma Ltd., Érd, Hungary
Background: Regional oxygen supply by red blood cells (RBCs) has a major im-
pact on brain functions. Our aim was to image RBC mass in the brain.
Material and methods: Male Wistar rats (n = 4) were anesthetized by Ketamine-
Xylasine. Catheters were inserted into the femoral artery and vein. RBCs were la-
beled with 99mTc using stannous pyrophosphate as reducing agent. Thirty min-
utes later, 1 mL of pre-treated arterial blood was withdrawn and gently mixed with 1
mL of 99mTc-pertechnetate solution of ~ 200 MBq activity. Labeled RBCs were re-
injected (70 MBq) 5 minutes pi. Two animals were treated by L-NAME. Scans were
acquired for control and at 44 minutes following the L-NAME injection. Animals
were sacrificed by washing out blood with saline infusion.
Cerebral RBC mass (CRBCM) was characterized by activities normalized to the
brain's volume.
Results: No activities were found in the thyroids and in the stomach, an evidence of
a larger then 99% purity of radiolabeling. Hot spots in the brain were detected at
venous sinuses and the circus of Willis. CRBCM decreased in the L-NAME treated
animals, 99mTc-activity became a magnitude smaller (0.03 mBq/cm3) after saline
infusion.
Conclusions: Quantitative NanoSPECT technology is efficient to assess regional
RBC mass in the rodent brain.
PRODUCTION OF A MTC-LABELED STANDARD STABLE SOLID MEAL
FOR GASTRIC MITILITY STUDIES
Gy.A. Janoki3, L. Balogh2, G. Janoki1, J. Lang
1Medi-Radiopharma Ltd., Budapest, Hungary, 2Radiopharmacy Laboratorium Ltd.,
Budapest, Hungary, 3National "FJC" Research Institute for Radiobiology
and Radiohygiene, Budapest, Hungary
Background: Studies of the gastrointestinal tract (GIT) have featured investigations
in nuclear medicine for more than 40 years. A wide range of radiolabeled test meals
have been used in GIT scintigraphy, and therefore the results are not comparable.
The American College of Radiology has issued practice guidelines for the perfor-
mance of GIT and consensus recommendations. Our aim was to develop and pro-
duce a standard stable solid meal (SSSM) with stable 99mTc-labeling that satisfies
the consensus recommendations.
Material and methods: Whole egg powder, egg substitute powder (for egg protein
— sensitive individuals), HSA, Sn-colloids, various Sn compounds, spices and for-
mulation substances were used to produce an SSSM that can be readily labeled
with 99mTc.The labeled SSSM was analyzed for labeling efficiency, stability, bio-
distribution and biological stability in beagle dogs.
Results: 99mTc-labeling can be accomplished simply by adding 99mTcO4 to SSSM
(LE ~ 100%). The in vitro stability of 99mTc-SSSM is suitable for our purpose. The
99mTc-SSSMs were incubated in artificial gastric fluid. The gastric fluid did not
contain free 99mTcO4. Gastric emptying (GE) scintigraphy revealed complete GE
after 24 h in these dogs. Target organs of free 99mTcO4– , e.g. the thyroid, were not
visible.
Conclusion: A kit has been compiled from suitable basic compounds that can be
utilized for the simple 99mTc-labeling of SSSM. This 99mTc-SSSM is of great value
for the scintigraphic investigation of GIT, GE and meets all the recommended stan-
dards. A lead-shielded heater kit has also been developed for the handling of the
99mTc-SSSM.
COMPARISON OF TUMORIGENICITY OF LIVER AND KIDNEY TUMORS
INDUCED BY N-NITROSODIMETHYLAMINE BY 18FDG UPTAKE AND THE
EXPRESSION OF GLUCOSE TRANSPORTERS
Gy. Trencsenyi1, T. Juhasz2, F. Bako1, T. Marian3, R. Salanki1, P Kertai4,
J. Hunyadi5, G. Banfalvi1
1Department of Microbial Biotechnology and Cell Biology, University of Debrecen,
Hungary, 2Department of Anatomy, Histology and Embryology, University of Debrecen,
Hungary, 3Institute of Nuclear Medicine, University of Debrecen, Hungary, 4Institute
of Preventive Medicine, University of Debrecen, Hungary, 5Department of Dermatology,
University of Debrecen, Hungary
Background: To estimate the tumorigenic potential, the 18FDG uptake and expres-
sion of facilitative glucose transporters have been suggested (Rastogi et al., 2007).
Malignant cells that are known to take up an increased amount of 18FDG, have
overexpressed GLUT-1 and/or GLUT-3. The aim of the study was to determine the
tumorigenic potential of two cell lines established from N-nitrosodimethylamine-
induced rat hepatocarcinoma (HeDe) and mesenchymal renal tumors (NeDe).
Material and methods: Fibroblast, HeDe and NeDe cell lines were used for in vitro
uptake studies of 18FDG glucose analogue. 106 cells were preincubated in PBS
containing 1 mM D-glucose. Preincubation was followed by the addition of 185
kBq 18FDG to each sample, then the cells were incubated for 15, 30 and 60 minutes
and the radioactivity was measured. Cells were cultured on coverglasses, fixed and
anti-GLUT-1,-3 antibodies were used to visualize the transporters.
Results: The uptake of 18FDG was 4 times higher in hepatocarcinoma cells and
nearly 3 times higher in mesenchymal renal tumor cells than in fibroblasts. The level
of GLUT-3 transporter was low in hepatocarcinoma cells, and high in mesenchymal
kidney tumor cells. In the case of  GLUT-1 the effect was reverse.
Conclusions: In vitro parameters support the view that the tumorigenic potential of
cancer cells cannot be determined by the expression of a single parameter. We
found that the higher 18FDG uptake correlate with the GLUT-1 and GLUT-3 expres-
sion, but not simultaneously. These data indicate that the expression of GLUT trans-
porters per se is not sufficient to judge tumorigenicity.
P31
IN VITRO AND IN VIVO EXAMINATIONS OF LU-177-EDTMP
Polyák1, T. Koncz1, G. Jánoki1, D. Máthé1, L. Balogh1, J. Környei3, Gy. Jánoki1
1National Research Institute for Radiobiology and Radiohygiene, Budapest, Hungary,
2Medi-Radiopharma Ltd., Radiopharmacy Ltd., Budapest, Hungary, 3Institute of Isotopes
CO., Ltd., Budapest, Hungary
Background: Phosphonate compounds can strongly adsorb onto bone surfaces,
which makes it possible to apply them in bone scintigraphy and palliative radio-
therapy of bone metastases. Earlier we made examinations with labeled phospho-
nates such as Tc-99m-MDP and Re-188-HEDP and now we have had the opportu-
nity to test EDTMP (Ethylene diamine tetramethylene phosphonic acid) which was
labeled  with Lu-177 isotope.
Material and methods: Lu-177 isotope was purchased from the Institute of Iso-
topes Ltd. in chemical form LuCl3 in 1mM HCl solution and Mediradiopharma Ltd.
provided EDTMP for our experiments. For quality control we applied Raytest MiniG-
ita device. We examined the labeling efficiency 20 min, 1 h, 6 h, 24 h, 2 d and 4 d
after application. Two healthy beagle dogs and three other dogs with spontaneous
osteosarcoma were injected with  Lu-177-EDTMP. The test material was followed
up by Nucline X-ring (Mediso) gamma camera 1, 2, 3, 6 and 24 hours, and 2, 4 and
7 days after injection. Images and ROI calculations were made using Interview soft-
ware.
Results: The evaluation of labeling efficiency by ITLC scanner and in vitro radio-
chemical stability at RT after application proved very good (99%). In the dogs with
osteosarcoma more than 50% of injected activity was adsorbed in the skeleton 3 h
after application, and daily follow-up showed that this adsorption was almost ulti-
mate/ complete. In bone tumors we could measure 2.5 to 8% of total injected activ-
ity, depending on the patient.
Conclusion: The excellent radiochemical purity and stability of Lu-177-EDTMP, good
adsorption effect of polyphosphonates, and favorable features of the Lu-177 iso-
tope can make this complex a good agent in the palliative radiotherapy of bone
metastases.
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INVESTIGATION OF THE DISTRIBUTION OF BIOLOGICALLY ACTIVE
MOLECULES IN TISSUES OF SMALL ANIMALS USING
AUTORADIOGRAPHY AND MINIPET IMAGING
T. Nagy, S.A. Kis, M. Emri, P. Mikecz, Gy. Trencsényi, Z. Hendrik, G. Opposits,
L. Trón, T. Márián
Department of Nuclear Medicine, Medical and Health Science Center, University of
Debrecen, Hungary
Background: The aim of the study was the implementation of methods for high
resolution imaging of PET radioligand distribution in mice and rat tissues.
Material and methods: Ex vivo auto-radiographic (Leica CM3600 whole body cry-
omacrotome) and in vivo PET (miniPET-II) techniques were used to study the accu-
mulation, binding and clearing of biologically active molecules (tumor and perfu-
sion tracers, receptor ligands) in tissues of small animals.
Results: The localization of tumor tissues in rats and mice applying PET tracers
(FDG, methionine, choline, FLT) and auto-radiographic slices combined with Phos-
phorimager evaluation is possible at a resolution of 50 microns . The procedure
also allows the demonstration of inhomogeneities (e.g. necrotic area) and eventual
metastases.  The efficiency of treatment can also be followed up if applied in rela-
tively large populations. Similarly, detailed quantitative data can be obtained from
receptor densities in case the experiments are carried out using labeled receptor-
ligands. In rat and mice models, the miniPET-II camera with a resolution of 1 mm
appears to be an efficient tool in drug development as well as in in vivo molecular
biology investigations. This technique allows the study of numerous physiological
and pathological processes provided an appropriate PET tracer is available.
Conclusion: Ex vivo imaging using the auto-radiographic technique and in vivo
imaging applying a miniPET-II scanner may play an important role in preclinical
and clinical investigations.
BLOCKING  THE  P-GP PUMP BY COMBINED TREATMENT MODIFIED
THE ACCUMULATION OF 99MTC-MIBI AND 18FDG IN MULTIDRUG
RESISTANT CELLS
Z. Fodor1, T. Márián1, P. Mikecz1, L. Galuska1, K. Goda2, Á. Tóth2, G. Szabó Jr2,
Z. Hernádi3, Z.T. Krasznai3
1Institute of Nuclear Medicine, University of Debrecen, Medical and Health Science
Center, Hungary,  2Department of Biophysics and Cell Biology, University of Debrecen,
Medical and Health Science Center, Hungary, 3Department of Obstetrics and
Gynecology, University of Debrecen, Medical and Health Science Center, Hungary
Background: It has been shown earlier that the combined application of modula-
tors and UIC2 antibody is an effective way of blocking P-glycoprotein (P-gp) func-
tion (J Pharm Exp Ther 2007; 320: 81–88). Here we describe the effect of this com-
bined treatment on the 18FDG and 99mTc-MIBI accumulation in carcinoma cells.
Material and methods: Human ovarian carcinoma cell lines were used. Following
the preincubation of tumor cells with P-gp modulators for 10 min they were further
incubated with UIC2 mAb and then washed. The cells were incubated in the pres-
ence of 18FDG, 99mTc-MIBI, rhodamine 123 (R123) and/or daunorubicin (DNR) at
37∞C, and the isotope accumulations and fluorescence intensities were measured.
Results: The decreased accumulation of R-123, DNR and 99mTc-MIBI by MDR pos-
itive cells was not reinstated by the incubation of the cells with UIC2 alone. Co-
incubation of the cells with UIC2+CSA resulted in the manifold binding of UIC2
and reverted the R-123, DNR and the 99mTc-MIBI accumulation in the P-gp+ cells. A
similar effect was shown by the combined treatment of the cells with UIC2+paclitaxel.
Blocking the P-gp pump with CSA+UIC2 or paclitaxel+UIC2 decreased the glu-
cose metabolic rate of the P-gp+ cells. Similar treatments of the P-gp– cells did not
result in a significant change in the R123, DNR and 99mTc-MIBI accumulation.
Conclusion:The combined treatment with UIC2 antibody and P-gp modulators ef-
fectively blocked the function of the P-gp pump in multidrug resistant cells and this
effect could be followed  using 99mTc-MIBI and 18FDG tumor-diagnostic tracers.
This work was supported by MEC-11/2008 grant.
EFFECT OF ANTHRACYCLINE DERIVATIVES ON THE [11C]CHOLINE
AND [18F]FDG ACCUMULATION IN CANCER CELLS
P. Mikecz1, T. Márián1, T. Miklovicz1, L. Galuska1, Z. Krasznai2, Á. Tóth2, K. Goda2,
L. Trón1, Z. Hernádi3, Z.T. Krasznai3
1Department of Nuclear Medicine, University of Debrecen, Medical and Health Science
Center, Hungary, 2Department of Biophysics and Cell Biology, University of Debrecen,
Medical and Health Science Center, Hungary, 3Department of Obstetrics and
Gynecology, University of Debrecen, Medical and Health Science Center, Hungary
Background: With the spread of PET studies it happens more and more often that
patients undergo chemotherapy. It is not yet known, how the chemotherapeutic
agents influence the outcome of the evaluation of a PET scan. Our aim was to study
how treatment with anthracycline derivatives modifies the accumulation of tumor-
diagnostic radiotracers in P-glycoprotein (P-gp) positive and negative cancer cells.
Material and methods: Human ovarian A2780 and A2780AD, human B lymphoid
JY, human epidermoid KB-3-1 and KB-V-1, and smooth muscle DDT1 MF-2 cell
lines were used. The tumor cells were pre-incubated with daunorubicin (DNR) and
doxorubicin (DOX), and the uptake of 18FDG and 11C-choline was measured.
Results: DNR treatment decreased the 11C-cholin accumulation of all of the inves-
tigated cells in a concentration dependent manner, while it did not modify the 18FDG
uptake of the cells significantly. The effect of DNR and DOX on choline accumula-
tion of P-gp positive cells was lower, than that of the P-gp negative pair. When
extracellular DNR was removed the blocking effect of the drug on the 11C-choline
uptake was smaller.
Conclusion: DNR and DOX treatment significantly decreased the 11C-choline ac-
cumulation of cancer cells. The blocking effect may have plasma membrane as
well as intracellular components. Our results indicate that the possible disturbing
effect of anthracycline medication should be taken into consideration during the
diagnostic interpretation of PET scans.
This work was supported by MEC-11/2008 grant.
EFFECT OF ONCOTHERMIA ON MRNA LEVELS OF HSP70A1A
AND HSP90AA1
T. Koncz1, G. Andócs2, P. Gálfi, L. Balogh1, A. Szász3
1National “FJC” Research Institute for Radiobiology and Radiohygiene, Budapest,
Hungary,  2Department of Pharmacology and Toxicology, Faculty of Veterinary Science,
Szent István University, Hungary, 3Department of Biotechnics, Faculty of Engeenering,
Szent István University, Hungary
Background: Electromagnetic hyperthermia has been a complementary method in
human cancer treatment for several years. Oncothermia (OT) is electromagnetic
heat delivery, applied in oncology. Our objective is to study the gene expression of
two human HSPs (HSP70A1A, HSP90AA1) at mRNA level using real-time PCR in
vivo after OT treatment.
Material and methods: OT utilizes modulated 13.56 MHz RF-current conduction in
capacitive coupled arrangement. In vivo, a HT-29-21 cell line-derived nude-mouse
xenograft double tumor model was used (one tumor was used as control, the other
one was treated) and treatments were done using a capacitivly coupled applicator.
Samplings were performed at different time-points after the treatments (1 h, 6 h, 12
h, 24 h, 48 h). First strand cDNA was synthetised from total RNA for quantitative
real-time PCR, and primers were designed by Primer3 based on sequences pub-
lished in NCBI database.
Results: Both HSPs showed increased mRNA level in every sample examined. Both
HSPs showed the highest expression level (hsp70 — about 10-fold, hsp90 — about
5-fold) at the same time-point (12 h after treatment). In the case of the first (1 h) and
the last (48 h) samplings only a slight difference could be observed in the relative
mRNA levels.
Conclusion: A significant increase was proved in vivo in the case of both HSPs, at
the mRNA level. So these methods could affect apoptosis through HSPs synthesis
and signal-transduction pathway, and might also trigger a specific immune-re-
sponse.
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STAGING PORTAL HYPERTENSION AND PORTOSYSTEMIC SHUNTS
USING DYNAMIC NUCLEAR MEDICINE INVESTIGATIONS
M. Dragoteanu, I.A. Balea, L.A. Dina, C.D. Piglesan, I. Grigorescu, S. Tamas
Sabin O. Cotul, “Professor Dr.Octavian Fodor” Clinical Emergency Hospital,
Cluj-Napoca, Romania
Background: The exploration of portal hypertension and portosystemic shunts,
and staging  chronic liver disease based on the pathophysiology of portal hemody-
namics have been in the focus of our interest for some time now.
Material and methods: Per-rectal portal scintigraphy (PRPS) was performed on
312 patients with chronic liver disease (CLD), and 231 of them also underwent liver
angioscintigraphy (LAS). The control groups included 25 healthy subjects. We de-
veloped a new model of PRPS interpretation by introducing two new parameters
called “liver transit time” (LTT) and ‘circulation time between right heart and liver’
(RHLT).
Results: The normal LTT value was established at 24 ± 1 s. Abnormal LTT had PPV
= 100% for CLD. Twenty seven non-cirrhotic patients had increased LTT up to 35 s,
the median value being 27 s. RHLT (42 ± 1 s) was not related to liver disease.
Cirrhosis was excluded in all the patients with PRSI < 5%. PRSI > 30% had
PPV = 100% for cirrhosis. Based on PRPS and LAS, we propose the classification
of CLD in 5 hemodynamic stages. Stage 0 is normal. In stage 1, LTT is increased,
but PRSI remains normal. In stage 2, LTT is decreased between 16–23 s, while PRSI
is increased between 5% and 10%. In stage 3, PRSI is increased by 10–30%, and
LTT becomes undetectable. Stage 4 includes patients with PRSI > 30%.
Conclusions: LTT allows both the detection of early portal hypertension and open-
ing of transhepatic shunts. PRSI is useful in CLD with extrahepatic portosystemic
shunts. Our hemodynamic model, staging the evolution of portal hypertension and
portosystemic shunts, is inclusively useful in the selection for Interferon therapy.
INVESTIGATION OF COLON TRANSIT IN CHILDREN WITH CHRONIC
IDIOPATHIC CONSTIPATION
E. Kócsák1, J. Gombos1, B. Poremba2
1Nuclear Medicine Laboratory, Borsod-Abaúj-Zemplén County Hospital, Miskolc,
Hungary, 2Pediatric Surgery and Traumatology, Borsod-Abaúj-Zemplén County Hospital,
Hungary
Background: In childhood, constipation is a very common problem with diverse
etiology. Most of the cases involve functional constipation. The types of chronic
idiopathic constipation (CIC) are as follows: slow colonic transit, functional fecal
retention, their combination, and constipation which is predominant in irritable bowel
syndrome. The first steps in diagnosing/treating the condition should involve the
exclusion of primary organic causes, as well as the metabolic, neurological and
iatrogenic ones.. Then special anorectal physiological investigations are needed.
Material and methods: In our laboratory, the aim of the radionuclide study was to
demonstrate the two types of CIC, the slow colon transit (SCT) and the functional
fecal retention (FFR). They make it easier for the clinician to plan the patient's treat-
ment. The radionuclide study is conducted as follows: after adequate pretreatment,
Tc-99m Fyton is administered peros, and images are collected at 2, 6, 12, 24, 30
and 48hours following administration. In children, the tracer normally reaches the
cecum in 6 hours and is evacuated in 30 to 48 hours. Slow transit is identified when
the tracer reaches the cecum in 6 hours, but most of the radioactivity  is  retained in
the proximal colon and transverse colon for 24, 30 and 48 hours. In the case of FFR
the tracer reached the rectosigmoid in 24 to 30 hours but was not passed for 48
hours.
After the evaluation of the specific studies, exploration of the causes and exact
diagnosis, the appropriate treatment always has to be planned individually. We
would like to demonstrate this by presenting 3 cases.
EXPERIENCE WITH SPECT/CT IN UNCOMMON ENDOCRINE DISEASES
Z. Szabó1, E. Mezösi2, E. Schimdt1, S. Szekeres1, C. Weninger3, K. Dercy3,
K. Zámbó1
1Department of Nuclear Medicine, University of Pécs, Hungary, 21st Department
of Internal Medicine, University of Pécs, Hungary, 3Department of Radiology, University
of Pécs, Hungary
Background: We aimed to demonstrate the clinical applicability of SPECT/CT
through case reports of uncommon endocrine disorders such as insulinoma and
ectopic Cushing's disease.
Material and methods: A total of 43 octreoscan examination was performed be-
tween July 2007 and March 2008. Two interesting cases are discussed here in de-
tail. In all cases, static, AP and PA SPECT scans were carried out on the chest and
abdomen at 24 and 48 hours after injecting the radiopharmacon. Additionally,
SPECT/CT was performed at 48 hours using a  Nucline DHV/CT Hybrid equipment.
Results: Most of the patients suffered from intestinal or pancreatic carcinoid tumor.
Insulinoma and ectopic Cushing's disease were revealed in 10% of the patients. In
the patient with ectopic Cushing's disease, focal accumulation of the radiopharma-
con was detected in the 9th segment of the right lung and behind the pancreas;
similarly, the CT scan showed topographically identical alterations in density. His-
tologically the tumor removed from the right lung was a typical carcinoid tumor with
ACTH receptors on the surface. In the patient with insulinoma, somatostatin recep-
tors of abnormally increased density were detected in the border region of the head
and body of the pancreas, while the CT scan suggested a circumscribed abnor-
mality with fatty-density. The histology of the tumor confirmed the diagnosis of in-
sulinoma.
Conclusion: Multimodal SPECT/CT provides clinically significant help in the local-
ization of ectopic and uncommon tumors supporting the indication of surgery and
improving the outcome.
SPECT EXAMINATION OF DÉJA VU ELICITED BY PALLIDAL DEEP BRAIN
STIMULATION
Zs. Szabó1, T. Auer2, N. Kovács2, A. Schwarcz3, I. Balás3, E. Tasnádi2,
P. Klivényi4, H. Jokeit5, F. Nagy2, J. Janszky2, T. Molnár6, K. Zámbó1
1Department of Nuclear Medicine, University of Pécs, Hungary, 2Department
of Neurology, University of Pécs, Hungary 3Department of Neurosurgery, University
of Pécs, Hungary, 4Department of Neurology, University of Szeged, Hungary, 5Swiss
Epilepsy Center, Zurich, Switzerland, 6Department of Anesthesiology and Intensive
Therapy, University of Pécs, Hungary
Background: Déja vu, as aura, is very common in temporal lobe epilepsy (TLE). In
a young woman with hemidystonia, déja vu was accidentally elicited by deep brain
stimulation. Functional imaging during déja vu had not been performed yet, there-
fore we aimed to determine the structures involved in generating déja vu.
Material and methods: Preoperative fMRI (at 1T) was performed for testing lan-
guage dominance, and then an electrode was inserted into the left globus pallidus
interna (GPi). Postoperative localization of the electrode was examined with coro-
nal and sagittal MP-RAGE. In agreement with the patient, “ictal” (during DBS stim-
ulation) and one week later “interictal” (normal stimulation) HMPAO-SPECT was
performed. The evaluation was carried out by subtraction ictal SPECT co-registered
to MRI (SISCOM).
Results: Hyperactivity was revealed in the right hippocampus, parahippocampal
gyrus, fusiform gyrus, cerebellum and superior temporal pole and in the left cere-
bellum, operculum, insula, lingual gyrus, precuneus and middle temporal gyrus. In
contrast, hypoactivity was found bilaterally in the fronto-parietal region.
Conclusion: Accidentally, a non-aura déja vu was elicited in a reproducible way by
DBS in a patient without epilepsy. Furthermore, déja vu related brain structures
(contralateral mesiotemporal hyperperfusion) became identifiable by using func-
tional imaging (SISCOM).
CLINICAL STUDIES
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CASE REPORT OF A RARE NUCLEAR MEDICINE EXAMINATION
Zs.F. Pluhár1, M. Lázár1, A. Csomor1, J. Kóbor2, A. Palkó1, 3, L. Pávics1, 4
1Euromedic Diagnostics Ltd., Szeged, Hungary, 2Department of Paediatrics, University
of Szeged, Hungary, 3Department of Radiology, University of Szeged, Hungary,
4Department of Nuclear Medicine, University of Szeged, Faculty of Medicine, Albert
Szent-Györgyi Medical and Pharmaceutical Center, Szeged, Hungary
Background: With the spread and development of morphological devices, and the
relatively easy access to these examinations, certain examinations using a radioiso-
tope have become less common. An example of the above is the liquorrhoea exam-
ination, which is very sensitive in detecting liquorrhoea.
Case report: A 4.5-year-old girl pricked the point of scissors into the inner corner of
her right eye. After the accident sanguineous secretion was discharged from her
right nostril, which was followed by clean liquid that was presumed to be liquor.
PlainCT scans of the skull (slice width 4 mm) did not confirm bone damage, but
suggested bilateral sinusitis. To prove liquorrhoea, radioisotope examination was
requested, which confirmed liquorrhoea by both the images and using quantitative
methods. Bone damage was confirmed and localized by thin-slice CT scans. In the
surgical exposure the 5 mm injury was tamponed. The patient is free of complaint
after the surgery.
Conclusion: The radioisotope examination clearly confirmed liquorrhoea. That is, if
the examinations do not confirm liquorrhoea unambiguously, first a radioisotope
examination is advised, which should be followed by a morphologic examination in
order to find the exact location of the injury.
P46
SPECT/CT IMAGING OF ABDOMINO-PELVIC INFECTIONS
E.W. Tekle1, M. Tusa2, M. Sinkó1, M. Rajtár1
1Department of Nuclear Medicine, Country Hospital Kecskemét, Hungary, 2Department
of Radiology, Country Hospital Kecskemét, Hungary
Background: Leukocyte scintigraphy (LS) can be inaccurate in the exact localiza-
tion of abdomino-pelvic infection (API) even in use of SPECT imaging, surgical
treatment, however, needs exact localization.
The aim of the study was to investigate the value of additional SPECT/CT imaging in
suspicion of API.
Material and methods: 50 patients (pts) (17 men, 33 women) with suspicion of API
underwent LS.
Radiopharmaceuticals: 1. 99mTc-HMPAO-labelled leukocytes 700 MBq: 29 pts; 2.
99mTc-antigranulocyte MAb 600 MBq: 21 pts.
Instruments: DHV SPIRIT dual headed SPECT and AnyScan SPECT/CT (Mediso).
Imaging after injection: ad 1 — 30, 120 minutes and 20 hours, ad 2 — 3 hours.
Images: whole body scan, abdominal/pelvic planar and SPECT scintigraphy (50
pts) and additional abdominal/pelvic plain low-dose CT+SPECT (7/50 pts).
Results: API was verified by final diagnosis in 22/50 pts whereas API was ruled out
in 28/50. API cases: tubo-ovarian abscess (4), adnexitis (6), subphrenic abscess
(2), abdominal wall abscess (2), liver abscess (1), pancreatic abscess (1), presac-
ral abscess (3), post-nephrectomy abscess (2), perianal abscess (1). Leukocyte
accumulation was detected by planar and SPECT imaging in 22/22 positive pts,
but in 6/22 pts the localization of accumulation was uncertain. The correct site of
infection was determined by SPECT/CT in 2 positive cases with uncertain localiza-
tion. LS was negative in 22/28 pts and there were 6 false positive cases.  API was
ruled out by SPECT/CT in 4/6 pts showing intraluminal cecal or urethral accumula-
tions. Further 2 cases of false positivity  weredue to abdominal wall stoma (SPECT/
CT was not done).
Conclusions: SPECT/CT can determine the exact  location and extent of API using
LS. Moreover, the accurate localization of physiologic leukocyte accumulation by
SPECT/CT could reduce the number of false positive results.
P47
SEASONAL APPEARANCE OF NEW BONE METASTASES IN BREAST
AND PROSTATE CANCER PATIENTS
V. Demeterné Bucs, E. Dombai, Gy. Vass, B. Török, E. Rizsányi, M. Sarkadi
Department of Nuclear Medicine, University of Pécs, Hungary
Background: The seasonal appearance of new bone metastases in breast and
prostate cancer patients was investigated on the bone scans.
Material and methods: 8405 whole body bone scans were performed from Janu-
ary 2006 to December 2008. Two hundred and ninety-one patients with breast can-
cer and 203 patients with prostate cancer were studied, in whom new hot spots
were found on their control bone scans. One or two control scans in 62% of the
cases, 3 or 4 control scans in 33%, 5 or more control scans in 5% of the cases were
performed.
Results: In the 291 breast cancer patients the appearance of new hot spots 33, 49,
43% were found in the spring months, 15, 15, 17% were found in the summer months,
32, 21, 17% were seen in the autumn months and 20, 15, 23% were seen in the
winter months. The results in the 203 prostate cancer patients were  as follows: 37,
32, 39% in spring, 20, 23, 15% in summer, 23, 20, 17% in autumn and 20, 25, 29% in
winter.
Conclusion: The new hot spots (metastases) appeared on the control bone scans
significantly more often in spring, while the progression rate was the least/was less
in summer.
TECHNOLOGISTS' SESSION
P48
SIGNIFICANCE OF SPECT/CT EXAMINATION IN BONE SCINTIGRAPHIES
E. Rizsányi, M. Sarkadi, Gy. Vass, V. Demeterné Bucs, E. Dombai
Department of Nuclear Medicine, University of Pécs, Hungary
Background: The aim of the study was the investigation of the etiology of hot spots
on the whole body bone scan by SPECT/CT fusion imaging.
Material and methods: Between July 2007 and December 2008, 4059 whole body
bone scans (WBBS) were performed; in 244 cancer patients they were completed
by SPECT/CT examination. There were 71 patients with breast cancer, 58 patients
with prostate cancer, 37 patients with lung cancer, 25 patients with malignant mel-
anoma and 53 patients with other tumors. The SPECT/CT investigations involved
the regions of  bone structure where the hot spots were found.
Results: In 78% of the cases the hot spots were in the spine while in 22% they were
detected in the skull, extremities and other localization. 7% all of the hot spots proved
to be bone metastases. In 12% of the patients with 2–4 hot spots on their scans
— 17% of the hot spots were verified as metastases and 83% happened to be
degenerative processes. In 15% of the cases the hot spots were the consequence
of operation, fracture, compression or other traumatic lesions. In 66% of the cases
only degenerative lesions were verified.
Conclusion: The completed SPECT/CT examinations after WBBS can give more
information about the etiology of the hot spots in the bones, which has a crucial role
in  providing efficient therapy. Our results suggest the importance of the careful
evaluation   of hot spots, because they are caused by metastases in only 7% of the
cases.
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WAYS AND WRONG WAYS IN  EVERYDAY NUCLEAR MEDICINE
I. Kunné Csuport, G. Dobos
Deptartment of Nuclear Medicine, State Health Centre, Budapest, Hungary
More than 20 different diagnostic examinations and therapies are performed in the
Department of Nuclear Medicine. Diagnostic protocols depend on the physical
and biological characteristics of the radiopharmaceuticals we use. Precise and ef-
ficient work demands teamwork on behalf of physicians and technologists alike.
The Close co-operation of the patients is also essential. The examinations in our
department are strongly influenced by the type, amount, availability of the radiop-
harmaceuticals (accumulation, excretion, gamma-energy, physical half-life, cam-
era-time, etc.). Appropriate assistant-doctor relation is needed for continuous ef-
fective work. Alarge share  of the work in a hot-lab is done by technologists. The
appropriate preparation of radiopharmacons is very important, because of the re-
quired high quality (purity, exact amount of activity). Almost every examination de-
mands different ways of patient preparation (stopping certain medications, hydra-
tion, etc.). Data acquisition and processing are also very variable. The distribution
of radiopharmacons in the human body is examined with different gamma cameras
(including double-head SPECT systems). Their technical parameters are defined
by the characteristics of the different radiopharmacons (physical characteristics of
SPECT, collimators, acquisition time). In dynamic examinations it is extremely im-
portant to prevent the patient from moving.  Our work in the Department of Nuclear
Medicine is regulated according to the Quality control handbook. All of our exami-
nations require close co-operation among doctors, assistants, therapists and pa-
tients; otherwise we can get lost in an endless labyrinth and it is the patient who will
be put at a disadvantage.
P49
ROLE AND PLACE OF THE TECHNOLOGISTS IN THE NUCLEAR
MEDICINE PROTOCOLS
M. Tóthné Bõdi, J. Nagy
Deptartment of Nuclear Medicine, State Health Centre, Budapest, Hungary
In the last years — owing to fast developing molecular medicine — a lot of new
diagnostic methods have been introduced into the practice of nuclear medicine.
From these new methods, we are routinely using some receptor- and immunoscin-
tigraphic investigations. In these types of examinations the accuracy of the assis-
tants' work is of great importance. When preparing the patients, we have to pay
special attention to their' medication. We have to give detailed information about
the examination (instructing them to stop certain medications, or to drink for hydra-
tion, etc.). In I-123-MIBG scintigraphy — used for patients with neuroblastoma or
phaeochromocytoma — the diagnostic value can significantly decrease, if the pa-
tient does not stop taking certain antihypertensive medications on the day prior to
the intervention. If we do not inform him to take iodine orally, the radiation burden to
the thyroid gland will be unnecessarily increased. Neuroblastoma is a pediatric
disease and the examination of children requires special skills and care (to avoid
movement artefacts).
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